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ABSTRACT 
 
B-cell chronic lymphocytic leukemia is the most common leukemia in the adult 
population of Western developed countries. In 2005, an estimated 9,730 adults in the 
United States will be diagnosed with B-CLL and an estimated 4,600 deaths will occur. 
B-CLL is a common heterogeneous malignant disease with variable outcome. B-CLL is 
divided into two groups based on whether somatic hypermutation is observed in the 
variable region of the immunoglobulin heavy-chain locus (IgVH). The two distinct 
groups are named mutated and unmutated. The B-CLL mutated group has a more 
favorable prognosis than the unmutated group. 
 
Gene expression profiling has been used successfully to decipher the biological and 
clinical diversity of many leukemias and lymphomas. Recently, other small RNAs 
(microRNAs) have been shown to be important in hematopoiesis. MicroRNAs are 
small 20-28 nucleotide RNAs that are believed to control many important cellular and 
developmental processes by posttranscriptional gene silencing, translational repression, 
and modulating epigenetic events.  
 
We are interested in whether microRNA expression correlates with the mutational 
status of IgVH. This study is significant in the following ways: (1) microRNAs may 
become surrogate markers for the mutational status of IgVH of B-CLL, which implies a 
more rapid diagnostic means as compared to the current practice, and (2) microRNAs, 
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in the particular context of B-CLL, may play some significant roles in a gene regulatory 
network that is further responsible for chromosomal abnormalities found in B-CLL. 
 
This thesis presents a study comparing microRNA expression in mutated and 
unmutated B-CLL groups. Instead of using a genome-wide expression profiling 
strategy, we selected a specific set of microRNAs based on their chromosome locations 
and mRNA targets. Specifically, we chose the following eight microRNAs (with their 
chromosomal abnormalities): mir16-1 (deletion 13), let-7i (trisomy 12), mir196-2 
(trisomy 12), mir26a-2 (trisomy 12), mir-34b (deletion 11), mir-125b (deletion 11), 
mir-181C (trisomy 19), mir-125a (trisomy 19). We used solution  hybridization  
assays to monitor the expression of microRNAs. We successfully characterized the 
microRNA expression in twelve B-CLL patient samples (eight mutated and four 
unmutated). Among the eight microRNAs examined, three (mir196-2, mir-125a, mir-
125b) are not expressed in the two B-CLL groups, four (mir16-1, mir26a-2, let-7i, 
mir-34b) have significant differences in expressions over the two groups, and one 
(mir-181c) has no significant difference in expressions over the two groups.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Chronic Lymphocytic Leukemia  
 
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia 
in the Western world (Döhner et al., 2000). CLL is divided into classes, B-CLL and 
T-CLL, based on their cell of origin (B-lymphoid cell or T-lymphoid cell). Ninety-
five percent of CLL cases in North America are B-CLL (Matutes and Catovsky, 
1993), and therefore this class of CLL is the focus of this thesis. Patients with B-
CLL usually have a gradual onset of symptoms and signs that are related to anemia, 
infection, and thrombocytopenia (Rozman and Montserrat, 1995). Blood tests 
showing lymphocytosis are usually the initial sign of B-CLL. Morphology of blood 
films and flow cytometry are the main methods used for a definitive B-CLL 
diagnosis. The average onset of B-CLL is 64 years. The outcomes of patients with 
B-CLL, however, are variable (Cheson et al., 1996). Patients can be grouped based 
on retrospective outcome studies into two categories; patients with good response to 
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therapy and long term survival and patients with poor response to therapy and 
progression to death (Cheson et al., 1996).  
 
At the cellular level, B-CLL cells are monoclonal B-cells that express mature B-cell 
markers (CD23 and CD5) and that have weak expression of surface 
immunoglobulins. B-CLL cells have a prolonged life span compared to normal 
lymphocytes (Lagneaux et al., 1998). B-CLL cells are more resistant to apoptosis, 
but they do not differ significantly in their rate of cell cycling compared to normal 
lymphocytes. The gene expression pattern of B-CLL cells suggests that they are 
related to memory or naïve B-lymphocytes (Küppers et al., 1999).  
 
The clinical course of B-CLL varies considerably. Approximately one third of 
patients never require treatment and die from causes unrelated to B-CLL.  Another 
one third of patients go through an initial indolent phase that is followed by 
progression of the disease. The remaining one third of patients have an aggressive 
disease at the onset and need immediate treatment (Schroeder et al., 1994). 
 
Biological markers for individual prognosis and prospective studies are important 
for patient treatment and management. Initial efforts to sub-classify B-CLL into 
distinct groups are based on the following criteria:  (i) whether the variable region 
of the immunoglobulin heavy-chain locus (IgVH) has undergone somatic mutation, 
and (ii) whether there is expression of CD38 on the cell surface. Several studies 
have shown that a more favorable prognosis is associated with B-CLL cells that 
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have undergone somatic mutation and have low CD38 expression (Damle et al., 
1999). B-CLL is commonly divided into two groups based on whether the B-CLL 
cells have undergone somatic mutation (Figure 1.1). Somatic mutation is quantified 
by measuring the DNA sequence differences between an expressed Ig heavy chain 
variable (V) region gene (IgVH) and its corresponding germline DNA sequence. 
When differences between the IgVH and germline DNA are greater than 2 %, then 
the IgVH is defined as having undergone somatic mutation (Fais et al., 1998). 
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1.2 Prognosis and Biological Cause of B-CLL: A Brief Survey 
 
The development of two different staging systems by Rai et al. (1975) and Binet et al. 
(1981) made it possible to divide patients with B-CLL into three prognostic groups: 
good, intermediate, and poor. This division is based on the following signs: 
lymphocytosis, splenomegaly, lymphadenopathy anemia, thrombocytopenia, and 
organomegaly. These staging systems do not correspond well with each other. Neither 
staging system enables physicians to accurately predict which patients in the good-
prognosis group will eventually have progressive disease.  
 
Serum levels of β-2-microglobulin, lactate dehydrogenase (Han et al., 1989), soluble 
CD23 (B-cell membrane protein), and thymidine kinase (Hallek et al., 1999) can help 
predict disease prognosis. Recent studies found that cytogenetic abnormalities, such as 
deletions in chromosome 13q14, 11q6 (Stilgenbauer et al., 2000), or somatic mutations 
in their immunoglobulin heavy-chain genes (Damle et al., 1999), are better predictors of 
rapid progression and survival. Mutational status of a patient’s IgVH gene is not a 
routine clinical test due to the cost and complexity. Therefore, many current studies are 
focused on finding surrogate markers that are independent of or correlated with IgVH 
mutational status and can be used to predict disease progression, survival, and treatment. 
Table 1.1 lists current markers that are used for B-CLL prognosis, including the Rai 
and Binet systems and serum level of β-2-microglobulin. Other markers in listed in 
Table 1.1 are discussed below. 
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Table 1.1. Current Prognostic Markers 
 
Staging System or Marker Clinical Practice Clinical Trail 
Staging(Rai or Binet) Yes Yes 
β -2-microglobulin Yes Yes 
Cytogenetics by FISH Yes Yes 
CD38 status Yes Yes 
IgVH mutational status No Yes 
ZAP-70 Not available Yes 
Thymidine Kinase No Yes 
 
Expression of CD38 and ZAP-70 correlates with the presence of unmutated IgVH genes 
and an unfavorable clinical outcome (Damle et al., (1999) and Durig et al., (2003)). 
However, the expression of CD38 and ZAP-70 in both mutated and unmutated B-CLL 
cells indicates lack of efficacy as a surrogate to classify the mutated and unmutated B-
CLL subgroups (Thunberg et al., 2001; Brian et al., 2003) 
 
Genomic aberrations in B-CLL cells are important independent predictors for B-CLL 
progression and survival. These findings have implications for designing risk-adapted 
treatment strategies (Döhner et al., 2000). A recent cytogenetic study on B-CLL 
analyzed survival in relation to chromosomal abnormalities detected using fluorescence 
in situ hybridization (FISH) (Gozzetti et al., 2004). Importantly, this study classified B-
CLL into five groups based on the following karyotypes; 17p deletion, 11q deletion, 
12q trisomy, normal karyotype, and 13q deletion. The median survival time was 
correlated with each karyotype.  B-CLL disease duration correlated 17p and 13q 
deletions. 17p showed the shortest survival time (32 months). 13q deletion had longest 
survival time (133 months). The genomic regions, affected by chromosomal deletions, 
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amplifications, and less frequently by translocations, still contain unknown tumor 
suppressor genes and oncogenes.  
 
IgVH mutation status and the pattern of genomic aberrations have a high predictive 
value for disease progression and survival in B-CLL patients. However, there are 
discrepancies in the literature with respect to correlations between genomic aberrations 
and mutational status of IgVH genes. For example, B-CLL patients with 13q deletion 
have a long survival time, however, Kröber et al., (2000) reported that almost half of 
unmutated B-CLL cases exhibited 13q deletion. This lack of correlation between 13q 
and mutated B-CLL patients suggests that inactivation of an unknown tumor suppressor 
in 13q may be important in both unmutated and mutated B-CLL cases.  However, 
correlations between B-CLL mutation status and genomic aberrations are reported by 
Carsten et al., (2003). In these studies, the favorable prognostic abnormality (13q 
deletion) is significantly more frequent in the mutated B-CLL group; whereas the 
prognostic unfavorable abnormalities (17p and 11q deletions) are almost exclusively 
found in the unmutated B-CLL group. Further, within the unmutated B-CLL group, 
patients with high-risk genomic aberrations, as defined by 17p and/or 11q deletion, have 
a significantly inferior survival probability (Ivan and Ian, 2003). Thus, the IgVH 
mutational status and genomic aberration likely give complementary prognostic 
information.  
 
Recently, genomic approaches have been used to classify B-CLL. In 2001, Rosenwald 
et al,. used lymphochip cDNA microarrays containing 17,856 human cDNAs to profile 
gene expression in B-CLL samples. They found that the expression of hundreds of other 
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genes correlated with the IgVH mutational status in B-CLL, providing insights into the 
biological mechanisms that lead to the divergent clinical behaviors of B-CLL patients 
(Rosenwald et al., 2001). 
 
More recently, Calin et al., (2004) used microRNAs (miRNA) microarrays to profile the 
miRNA expression in B-CLL patients. They found low level expression of mir-16-1 in 
B-CLL patients harboring deletions at 13q14. They also found a distinct B-CLL 
miRNA signature composed of five differentially expressed miRNAs (mir-186, mir-
132, mir-16-1, mir-102, and mir-29C) that distinguished mutated and unmutated B-CLL 
groups. 
 
1.3 microRNAs 
 
miRNAs are endogenous 21-24 nucleotide (nt) RNAs that mediate post-transcriptional 
gene regulation by pairing with the 3' untranslated region of messenger RNAs (mRNA) 
and repress translation (Moss, 2003). miRNAs are found in mammals, fish, worms, 
flies, yeast and viruses (Mourelates et al., 2002; Ambros et al., 2003; Aravin et al., 
2003; Dostie et al., 2003; Kim et al., 2003). Recent reports suggest a role for miRNAs 
in development, cell differentiation, apoptosis, and cancer (Baehrecke, 2003; Bartel, 
2004; Calin et al., 2004). 
 
miRNA expression in animals involves at least two processing steps (Lee et al., 2002). 
miRNA precursors are expressed as long primary transcripts (60-110 nt), called the 
primary microRNA (pri-miRNA), which may be polycistronic. pri-miRNAs are 
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processed in the nucleus (Lee et al., 2002) by the nuclease Drosha, which yields one or 
more hairpin precursor sequences (pre-miRNAs or stRNA, small temporal RNA). Pre-
miRNAs are exported to the cytoplasm by means of the Exportin-5 pathway (Lund et 
al., 2004). Cytoplamic pre-miRNAs are processed by the nuclease Dicer. One strand 
from the RNA duplex is complexed with a protein complex containing argonaute 2, 
Gemin3, and Gemin4 and the remaining strand is degraded (Lund et al., 2004). The 
ribonucleoproteins complexes are classified as RNA induced silencing complexes 
(RISC). RISC causes either target mRNA degradation or translation repression (Figure 
1.2) (Schwarz and Zamore, 2002). Nelson et al., (2003) suggested the term 
RISC/miRNP endonuclease for the catalytic activity of RISC and miRNPs, since 
miRNAs with extensive sequence complementarity to their mRNA targets can trigger 
RNA interference (RNAi) (Andrea and Peter, 2004). If a miRNA is completely 
complementarily to its target mRNA, degradation of this mRNA will occur. If a miRNA 
is partially complementarily to its target mRNA, then translation of this mRNA will be 
inhibited. 
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Figure 1.2. The development of the mature miRNAs (Bartel, 2004). Pri-miRNAs are 
cleaved by Drosha in the nucleus yielding smaller pre-miRNAs. pre-miRNAs are 
transported to the cytoplasm, where Dicer, a member of the RNAse III nuclease family, 
further processes them to yield mature miRNAs. miRNAs associate with RNA induced 
silencing complex (RISC), which affects the silencing of target mRNA molecules. If a 
miRNA is complementary to its target mRNA, degradation of this mRNA will occur. If 
a miRNA is partially complementary to its target mRNA, then translation of this mRNA 
will be inhibited. 
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1.3.1 miRNAs and Hematopoietic Cancers  
 
miRNAs play important regulatory roles in animal and plant development at the post-
transcriptional level. Many miRNAs cloned from mouse bone marrow cells are 
differentially regulated in various hematopoietic lineages, suggesting that they might 
influence hematopoietic lineage differentiation (Chena and Lodish, 2005). For example, 
mir-181, a miRNA specifically expressed in B-cells within mouse bone marrow, 
promotes B-cell differentiation when expressed in hematopoietic stem/progenitor cells. 
Some human miRNAs are associated with leukemias (Calin et al., 2002). mir-15a/mir-
16 locus is frequently deleted or down-regulated in B-CLL patients and mir-142 is at a 
translocation site found in a case of aggressive B-cell leukemia. Collectively, these 
results indicate that miRNAs may be important regulators of mammalian 
hematopoiesis.  
 
1.3.2 miRNAs and Cancer-Associated Genomic Aberrations 
 
Many miRNAs are located at sites of cancer associated chromosomal aberrations. For 
example, the homozygous deletions of mir-15a and mir-16a cluster associate with 
aberration of deletion 13q14 in B-CLL (Calin et al., 2002). miRNAs that are located in 
the bands of chromosomal aberrations should predict low risk and high risk groups of 
B-CLL patients, Using microRNA microarrays, Calin et al. (2004) reported low level 
expression of mir-16-1 in leukemia harboring deletions at 13q14 (P=0.03, ANOVA), a 
chromosomal aberrations associated with prognosis of B-CLL. They also found a 
distinct miRNA signature composed of five differentially expressed miRNAs (mir-186, 
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mir-132, mir-16-1, mir-102, and mir-29C) that distinguished mutated and unmutated B-
CLLs. mir-16-1 and mir-132, are associated with B-CLL chromosomal aberrations 
d13q14 and d17p13.3, respectively. Michael et al., found that the mir-143 and mir-145 
miRNA cluster is located at fragile sites in genomic regions. The expression of this 
miRNA cluster is down-regulated in colon cancers (Michael et al., 2003). 
 
1.4 Hypothesis  
 
The main hypotheses of this thesis are that the miRNAs have significant differences in 
expression between mutated and unmutated B-CLL patient groups and that miRNAs 
located in genomic regions that are associated with B-CLL aberrations are useful for 
classifying B-CLL.  
 
1.5 Specific Aims 
 
        We pursued the following specific aims to test our hypotheses. First, we identified 
miRNAs located at chromosomal aberrations sites associated with B-CLL. Second, we 
collected a set of peripheral blood samples from B-CLL patients and determined their 
mutational status. Third, we monitored the expression of a limited set of miRNAs in B-
CLL patient material. Fourth, we correlated miRNA expression with mutational status. 
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CHAPTER 2 
Materials and Methods 
 
We performed the following tasks to compare the miRNA expression between mutated 
and unmutated B-CLL groups. In Task 1, we obtained B-CLL cells from patients. In 
Task 2, we obtained total RNA and cDNAs from B-CLL cells. In Task 3, we classified 
the mutational status of patients and divided them into mutated and unmutated B-CLL 
groups. In Task 4, we quantified miRNA expression levels. In Task 5, we analyzed the 
significant differences in miRNA expressions in the mutated and unmutated B-CLL 
groups. Figure 2.1 shows a relationship among these tasks and highlights their inputs 
and outputs. The details of these tasks are presented below. 
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Figure 2.1. Relationship among task inputs and outputs. A: Peripheral Blood; B: Total B-
cells. (B=B1+B2); C: IgVH Gene Sequence; D: Mutational Status; E: miRNA; F: miRNA 
Expression Level. 
2.1 Task 1: Collection of B-CLL Samples 
 
2.1.1 Collection of Patient Material 
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We obtained thirty patient peripheral blood samples with the consent of patients 
diagnosed with B-CLL at the Royal University Hospital, Saskatoon, Saskatchewan. We 
chose patient samples for further analysis based on the percentage of white blood cell 
count (>5000/mm3), and the percentage of B-cells in the white blood cells (> 95 %). We 
confirmed the B-CLL patient diagnosis using morphologic and immunophenotypic 
criteria. All B-CLL samples in this study were collected before any therapy was given.  
 
2.1.2 Isolation of B-CLL cells 
 
We used the following procedure to obtain B-CLL cells. We diluted anti-coagulated 
blood cells to a final volume of 30 ml in 1×phosphate-buffered saline (PBS). We 
layered the diluted anti-coagulated blood cells onto 9 ml of Ficoll Paque. We 
centrifuged the sample at 400 g for 20 minutes at room temperature. We discarded the 
upper layer of plasma and transferred the mononuclear layer to a 15 ml tube. We diluted 
the mononuclear layer with 1×PBS to a final volume of 10 ml. We centrifuged the 
diluted mononuclear cells at 400 g for 5 minutes at room temperature. We decanted the 
supernatant and re-suspend the cells in 10 ml of PBS. We removed 30 µl of cells and 
counted the cells by staining them with same volume of trypan blue. We washed the 
cells an additional two times using the same procedure described above. We re-
suspended the final cell pellet at a concentration of 1 × 107 cell/ml in 10 % DMSO 
(Dimethyl Sulphoxide) and 40 % FCS (Fetal Calf Serum) and stored the cells at -80 °C.  
 
2.2 Task 2: RNA Isolation, cDNA Synthesis, Amplification of IgVH DNA, and DNA 
Sequencing 
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2.2.1 RNA Isolation 
 
We used the following protocol to isolate total cellular RNAs from frozen B-CLL cells. 
We thawed the frozen cells, pelleted them by centrifugation, and re-suspended them in 
Trizol reagent (1×107 cells per ml Trizol reagent). We lysed the cells by vortexing them 
for 1 minute at room temperature. We added 0.2 ml of BCP (1-Bromo-3-Chloro-
Propane) to each milliliter of lysed cells in Trizol reagent. We vortexed the mixture for 
15 seconds and incubated it at room temperature for 2-3 minutes. We centrifuged the 
mixture for 15 minutes at 4 °C at 12000 g. We transferred the aqueous phase to a fresh 
tube and added 0.5 ml isopropyl alcohol per milliliter of Trizol reagent to precipitate 
RNA. We incubated the mixture (the aqueous phase with isopropyl) at room 
temperature for 10 minutes and centrifuged it for 10 minutes at 4 °C at 12000 g. We 
discarded the supernatant and washed the RNA pellet in 0.5 ml of 75 % ethanol. We 
vortexed the mixture and centrifuged it at 7500 g at 4 °C for 5 minutes. We discarded 
the ethanol supernatant and air-dried the pellet for 10-15 minutes. We dissolved the 
pellet in the RNase-free water (~ 25 µl). We determined the concentration of the 
isolated RNA using an UV spectrometer at an OD (Optical Density) of 260 and 280 nm. 
 
2.2.2 cDNA Synthesis 
 
We added 1 µg total RNA to a 20 µl reaction containing: 50 µmol of random hexamer 
primers (PE, Foster City, CA), 200 U of Super Script II, First Strand Buffer (50 mM 
Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2), 10 mM of DTT, 20 U of RNase 
inhibitor, and 0.5 mM of each dNTP (GIBCO BRL, Gaithersburg, MD). We incubated 
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the reaction mixture for 10 minutes at 21 °C and then for 30 minutes at 42 °C, using a 
GeneAmp System 2400 (PE, Foster City, CA), to produce the cDNA. We heated 
reaction mixture at 95 °C for 5 minutes to inactivate the Super Script II reverse 
transcriptase. 
 
2.2.3 Polymerase Chain Reaction (PCR) Amplification of IgVH cDNA 
 
We amplified 1 µl of cDNA using GeneAmp System 2400 (PE, Foster City, CA) using 
the following 50 µl PCR reaction:  PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl), 
1.5 mM MgCl2 (for VHL1, VHL3, and VHL5) or 2.0 mM MgCl2 (for VHL2, VHL4, 
and VHL6), 0.2 mM of each dNTP, and 1.25 U Hotstar polymerase (Hot Star Qiagen). 
We added 50 pmol of downstream primer corresponding to a consensus sequence (JH, 
5’- ACCTGAGGAGACGGTGACC-3’) at the end of the J-region with 50 pmol of one 
of the following upstream primer corresponding to 1 of the 6 human VH leader 
sequences:  
 VHL1, 5’- CCATGGACTGGACCTGGAGG- 3’;  
VHL2, 5’-ATGGACATACTTTGTTCCAGC-3’; 
VHL3, 5’-CCATGGAGTTTGGGCTGAGC-3’; 
VHL4, 5’-ATGAAACACCTGTGGTTCTT-3’; 
VHL5, 5’-ATGGGGTCAACCGCCATCCT-3’; 
VHL6, 5’-ATGTCTGTCT CCTTCCTCAT-3’, 
We performed one cycle of amplification by pre-activating “hotstar” DNA polymerase 
at 95 °C for 20 minutes, annealing the primers at 65 °C for 4 minutes, and extending the 
primers at 72°C for 1 minute. Then, we performed 40 cycles of amplification at the 
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following settings: 95 °C for 1 minute, 61 °C for 30 seconds, and 72 °C for 1 minute. 
Finally, we incubated the PCR reaction mixture at 72 °C for 6 minutes to produce the 
final PCR product. We analyzed the PCR product on a 2 % agarose gel stained with 
ethidium bromide and visualized the PCR product by exposing it with a UV 
Transilluminator (Bio-Rad Inc). We stored the PCR product at -20 °C. 
 
2.2.4 Sequencing of IgVH Regions 
 
We determined the concentration of PCR products by running them together with a 
standard marker on a 2 % agarose gel stained with ethidium bromide. Based on the 
intensity of the PCR product relative to the standard pre-made marker, we determined 
the concentration of individual PCR-products. We sequenced the PCR-products (1 
µg/each) using ABI PRISM: 310 Genetic Analyzer. 
 
2.3 Task 3: Classification of IgVH Mutational Status of Patient Samples 
 
We classified B-CLL cells into mutated and unmutated groups based on the mutational 
status of the IgVH region. We calculated the mutational status by comparing the patient 
IgVH gene sequence to its corresponding germline sequence. If the IgVH gene sequence 
differs from the germline sequence by > 2 %, then we classify the B-CLL as mutated. 
The reliability of this approach can be enhanced with an approach proposed by Lossos 
et al. called “antigen selection”. Details of these two approaches are given below 
(Lossos et al., 2000).  
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2.3.1 Comparing Patient IgVH sequence to Germline Sequence 
 
We aligned patient IgVH gene sequences to immunoglobulin germline gene sequences 
that we obtained from the Immunoglobin Basic Local Alignment Search Tool (Ig 
BLAST) database (http://www.ncbi.nlm.nih.gov/igblast/) (National Center for 
Biotechnology Information, Bethesda, MD). Ig BLAST program identifies the IgVH 
germline sequence that is most similar to the patient IgVH sequence. When the patient 
IgVH differs from the germline IgVH sequence by more than 2 %, then B-CLL cells are 
classified as mutated. If the patient IgVH differs from the germline IgVH sequence by 
less than 2 %, then B-CLL cells are unmutated B-CLL. 
 
2.3.2 Antigen Selection of B-CLL Cells 
 
Lossos et al., (2000) developed an algorithm to calculate the probability that a B-Cell 
has undergone antigen selection (http://www-stat.stanford.edu/immunoglobin). The 
method used to predict whether antigen selection of Ig genes has occurred is based on 
assessing replacement (R) and silent (S) mutation in the complementary-determining 
regions (CDR) and framework regions (FR). Replacement mutation is a point mutation 
in a codon that causes a different amino acid to occur in the protein. Silent mutation is a 
point mutation in a codon, which due to the degeneracy of the genetic code, results in 
the same amino acid in the protein. The distribution of replacement (R) mutations and 
silent (S) mutations within the CDRs and framework regions (FRs) is used to determine 
whether the antigen selection occurs. If a more R mutations than S mutations occur in 
the complementary-determining region (CDR) than in the framework region (FR), then 
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the antigen selection is predicted to have occurred. During antigen selection, somatic 
mutation occurs, which is predicted to give rise to the mutated B-CLL group.  
 
To calculate the probability that a B-CLL cell has undergone antigen selection using 
Lossos’ algorithm, the following information is needed. First the germline sequence for 
the IgVH region is obtained from http://www.ncbi.nlm.nih.gov/igblast. Second, the 
germline sequence is divided into FR1, FR2, FR3, CDR1, and CDR2 regions. Third, the 
numbers of R and S mutations in these regions are calculated. This information is used 
to obtain P-values for whether antigen selection has occurred.  
 
2.4 Task 4: miRNA Isolation, miRNA Probe Construction, and miRNA Detection 
 
2.4.1 miRNA Isolation  
 
We used 5×107 frozen patient B-CLL cells to isolate miRNA using mirVana™ miRNA 
Isolation Kit 1560 (Ambion). The specific details of the isolation protocol are described 
in the mirVana™ miRNA Isolation Kit 1560 manual. The basic concepts behind the 
miRNA isolation protocol are as follows. The first step in miRNA isolation is to disrupt 
B-CLL cells in denaturing lysis buffer. The second step is to subject the samples to an 
Acid-Phenol:Chloroform extraction, which removes most of the protein and DNA from 
the sample (Chirgwin et al., 1979). The third step is to enrich the sample for small 
RNAs.  To do this, large RNAs are removed from the sample by immobilizing them on 
a glass filter. Large RNAs are bound to the glass filter when they are applied to the 
glass filter in a solution containing a low concentration of ethanol (25 %).  
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Smaller RNAs do not bind to the glass filter at this ethanol concentration. Small RNAs 
can be isolated by the glass filter by increasing the ethanol concentration to 55 %. The 
detailed procedure for the isolation is described as follows (see also Figure 2.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ig h fd e c b a 
5×107 cells washed 
twice with 1×PBS Spin at 10000g
Lysis/Binding 
Buffer Elution buffer 
Collect filtrate 
Acid phenol
Transfer the top layer
Transfer the “pass through” a 
new filter tube 
Wash with “1, 2&3” 
Homogenate Additive 
miRNA 
Figure 2.2. The isolation process for miRNA. After the cells were washed and pelleted 
(a), the first step is to disrupt B-CLL cells in denaturing lysis/binding buffer which is 
provide in kits, then the samples were subjected to an Acid-Phenol:Chloroform extraction 
to removes most of the protein and DNA from the sample (b). The aqueous phase was 
transferred to a fresh tube and the volume of the transferred aqueous phase was recorded
(c). 1/3 volume of the 100% ethanol was added to the RNA product (d), then centrifuge 
the mixture to pass through a filter cartridge (e), first filter cartridge, and collected the 
filtrate, and record the volume of filtrate (f). 2/3 volume of the 100% ethanol was added to 
the filtrate, then transfer the mixture into a second filter cartridge and centrifuged (g).
After washed with wash solution 1, 2 & 3 that are provide in kits (h), elute the small RNA 
from the filter (i). 
 
We measured the small RNA concentration using a smartspecTM 3000 UV spectrometer 
(Bio-Rad Inc). We analyzed 0.25 µg of small RNAs on a 15 % polyacrylamide gel 
(together with 0.25 µg mir-16) and visualized the RNA by staining with cyberGold 
(Molecular Probes Inc) and monitoring fluorescence using an UV Transilluminator 
(Bio-Rad Inc). We normalized the small RNA concentrations from different patient 
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samples using a common RNA (usually the 5.8S ribosomal RNA). We chose one 
patient sample as the standard to normalize all patient samples against. The recovered 
small RNAs are stored it at –80 °C until further analysis. 
 
2.4.2 Solution Hybridization Assay to Detect miRNA  
 
We used the solution hybridization assay developed by Ambion (mirVana miRNA 
detection kit) to detect specific miRNAs presents in the patient samples. The specific 
details of the isolation protocol are described in the (mirVana miRNA detection kit) 
manual. The basic concepts behind the miRNA isolation protocol are summarized in 
Figure 2.3. miRNAs are detected in small RNA patient samples by hybridizing specific 
miRNAs to a radiolabeled antisense RNA probe. Unhybridized probes and miRNA are 
then removed from the sample by a ribonuclease digestion. Double-stranded 
radiolabeled probes that are protected RNase digestion are purified and detected using a 
denaturing polyacrylamide gel.  
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Figure 2.3. Solution Hybridization Assay. miRNAs in small RNA patient samples are 
detected by hybridizing with a specific radiolabeled antisense RNA probe. (a) miRNA 
probe is mixed with the sample RNAs. (b) The miRNAs are hybridized to their 
complementary probes. (c) The mixture is treated with RNase to digest unhybridized 
probe. (d) Double-stranded radiolabeled probes that are protected against RNase 
digestion are detected using a denaturing polyacrylamide gel. 
d: Detection c: RNase digestion b: Hybridization a:miRNA targets 
probe 
 
The solution hybridization assay is divided into three steps: probe construction, miRNA 
RNase protection assay, miRNA detection. 
 
2.4.3 Probe Construction 
 
We prepared high specific-activity 32P-labeled antisense RNA probes using in vitro 
transcription. The in vitro transcription reaction is consists of four steps, which are 
summarized in Figure 2.3.  In the first step, DNA oligonucleotide nucleotide templates 
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are designed to construct antisense probes for specific miRNAs. At the 5’ end, the DNA 
template contains a sequence that is identical to the miRNA that will be detected. At the 
3’ end, the DNA template contains an eight base sequence complementary to the 3' end 
of the T7 Promoter primer. The DNA templates for the eight miRNAs used in this study 
are listed in Table 2.1. Several of the DNA templates contain four T bases between the 
miRNA sequence and the T7 complementary region. The extras Ts allow several probes 
to be assayed simultaneously. The addition of T residues generates an antisense RNA 
probe that contains a stretch of A residues that cannot be cleaved by RNases A nor T1. 
(Ausubel et al., 2004). The addition of 4 Ts residues to the DNA oligonucleotide 
nucleotide template sequence is sufficient for size resolution from the 0 T DNA 
oligonucleotide nucleotide template on the PAGE gels used for multi-probe solution 
hybridization assays.  
 
Table 2.1. Eight selected miRNAs: Their mature sequences and DNA oligonucleotide  
templates 
 
miRNA 
miRNA Sequence (Mature) and DNA oligonucleotide  for T7 miRNA 
Probe (+4Ts and 0T) 
hsa-miR-34b 
14AGGCAGUGUCAUUAGCUGAUUG35 
 AGGCAGTGTCATTAGCTGATTGTTTTCCTGTCTC 
hsa-miR-125b 
15UCCCUGAGACCCUAACUUGUGA36   
  TCCCTGAGACCCTAACTTGTGACCTGTCTC 
hsa-miR-16-1   
14UAGCAGCACGUAAAUAUUGGCG35   
  TAGCAGCACGTAAATATTGGCGCCTGTCTC 
hsa-miR-196-2   TAGGTAGTTTCATGTTGTTGGGTTTTCCTGTCTC 
25UAGGUAGUUUCAUGUUGUUGGG46   
hsa-miR-26a-
2   
14UUCAAGUAAUCCAGGAUAGGCU35   
  TTCAAGTAATCCAGGATAGGCTCCTGTCTC 
hsa-let-7i 
6UGAGGUAGUAGUUUGUGCU24   
 TGAGGTAGTAGTTTGTGCTTTTTCCTGTCTC 
hsa-miR-181c 
27AACAUUCAACCUGUCGGUGAGU48 
  AACATTCAACCTGTCGGTGAGTTTTTCCTGTCTC 
miR-125a   
15UCCCUGAGACCCUUUAACCUGUG37   
  TCCCTGAGACCCTTTAACCTGTGTTTTCCTGTCTC 
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In the first step, mature miRNA sequences were obtained from ‘Sanger Rfam’ database 
(http://www.sanger.ac.uk/Software/Rfam/mirna/index.shtml).  
 
In the second step, a double-stranded transcription template is prepared. The 
oligonucleotide nucleotide template is annealed to the T7 Promoter Primer (Figure 
2.4b). The T7 promoter primer and the oligonucleotide nucleotide template are 
extended using Exo-Klenow DNA polymerase (Figure 2.4c).  
 
In the third step, the double-stranded DNA template is transcribed using T7 phage RNA 
polymerase (Figure 2.4d). The RNA polymerase binds to the double-stranded template 
and separates the two strands of DNA. The RNA polymerase uses the 3’ to 5’ strand as 
a template to synthesize a complementary 5’ to 3’ RNA transcript. The RNA transcript 
was radiolabeled by incorporating [α-32P] UTP (Amersham Inc) in vitro transcription 
reaction.  The DNA template in the reaction is removed using DNase I. We purified the 
RNA probes made by in vitro transcription to remove transcripts that are shorter than 
the full-length probe because these shorter products may cause “background” smears 
and/or spurious protected bands in the assay. We purified the RNA transcripts using a 
denaturing polyacrylamide gel. We determined the yield and the specific activity of 
radiolabeled transcripts measuring and comparing the total amount of radiolabel present 
in the reaction mixture using a scintillation counter (BECKMAN Inc). 
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(c)
3’ 
3’5’ 
5’
5’
3’C C T G T C T C  
G G A CA G AG 
3’
5’ 
3’ 5’ C C T G T C T C 
(d)
(a) 
 Target sequence  
T7 promoter 
C C  T G  T C T C  
G G A C A G A G  
Transcribe with T7 RNA polymerase 
Antisense miRNA 
Fill in Klenow DNA polymerase
T7 
Anneal DNA 
Target sequence 
Design DNA 
3’ 5’ 
Target miRNA
3’ G G A C A G A G 5’ 
(b)
Figure 2.4. miRNA probe construction. (a) The DNA oligonucleotide nucleotide has 
the same sequence as its target miRNA, except the U residue is replaced by T 
residue. An eight base sequence which is complementary to the 3' end of the T7 
Promoter Primer was added to the 3’end of oligonucleotide . (b) T7 promoter primer 
was annealed to the oligonucleotide nucleotide. (c) Double-stranded DNA template 
was synthesized using Klenow DNA polymerase. (d) miRNA probe was generated 
using T7 RNA polymerase. Two extra Gs are added during the transcription
reaction.  
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miRNA probe construction for mir-16 and mir-16+4 are outlined below. 
 
mir-16 Sequence: 5'-UAGCAGCACGUAAAUAUUGGCG-3' 
DNA template for mir-16:  5'-TAGCAGCACGTAAATATTGGCGCCTGTCTC-3' 
Mir-16 probe: 3'-AUCGUCGUGCAUUUAUAACCGCGGACAGAGGG-5' 
Product from solution hybridization assay: 3'-AUCGUCGUGCAUUUAUAACCGC-5' 
 
mir-16+4 Sequence: 5'-UAGCAGCACGUAAAUAUUGGCG-3' 
DNA template for mir-16 +4:  
5'-TAGCAGCACGTAAATATTGGCGTTTTCCTGTCTC-3' 
mir-16+4 Probe: 3'-AUCGUCGUGCAUUUAUAACCGCAAAAGGACAGAGGG-5' 
Product from solution hybridization assay: 
3'-AUCGUCGUGCAUUUAUAACCGCAAAA-5' 
 
2.4.4 miRNA Detection: miRNA RNase Protection Assay 
 
Specific antisense RNA probes are used to detect miRNAs present in small RNAs 
samples from patient material.  If a specific miRNA probes is present in the sample, 
then it will protect the RNA probe from degradation by RNase. The amount of protected 
probe is directly proportional to the amount of miRNA in the sample. Typically, we use 
0.5 to 5 µg of small RNA sample for the RNase protection assay. We add 32P-labeled 
RNA probe in five-fold molar excess over the target miRNA. In most cases 5×10 4 cpm 
(0.023 µCi) of highly specific activity probes meet this requirement. 
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In addition to the small RNA patient samples, we use two miRNA controls and one 
standard marker for each probe in the experiment. The first control contains miRNA 
probe and no miRNA or RNase and it is used to assess probe quality and recovery 
(negative control). The second control contains miRNA probe and no miRNA and it is 
used to assess non-specific background signals and verify that probe digestion is 
complete (positive control). The standard marker contains miRNA probe and standard 
miRNA. 
 
The total amount of RNA in each sample and control should be roughly equal (+/– 10 
%) in order to ensure that the RNase digestion conditions are similar in each. If the 
amounts of sample RNAs vary, we used yeast RNA to adjust the total amount of RNA 
in each hybridization reaction, plus controls up to 5 µg.  
 
The antisense RNA is hybridized to the miRNAs by heating it to 95 °C and slowly 
cooling to 52 °C over a period of 2 hours.  This step denatures the RNA, specifically 
reducing the effect of some secondary structure that may be formed during 
hybridization. The hybridized RNA samples are treated with RNase A and T1 to digest 
RNAs that do not form complexes with the antisense RNA probe. The protected RNA 
probes are precipitated and detected using a denaturing polyacrylamide gel. The amount 
of protected 32-P antisense RNA probe protected was quantified using a phosphorimager 
(Bio Rad Inc).  
 
2.5 Task 5: Statistical Analysis of miRNA Expressions 
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We determined the intensities of miRNA bands from the solution hybridization 
detection gels using a phosphoimager (Bio Rad Inc). We used the significance test 
facility in SAS (Statistical Analysis Software) software (SAS Institute, Cary NC) to 
evaluate whether there are significant differences in the miRNA expression between the 
mutated and unmutated B-CLL groups.  
 
2.5.1 Statistical Problem Formulation 
 
The evaluation problem can be defined as a significance test problem in statistical data 
analysis. For the significance test for two groups (the mutated and unmutated B-CLL 
groups), we used the t-test (Appendix A). Assume that for a particular miRNA (e.g., 
mir-26a-2) we have its expressions (Intensities from phospoimager) in the two groups 
as follows: 
 
(i) In the mutated group: 4271839.8, 5154553.9, 2639191, 3606797, 3216792.2, 
3688059.3, 1894745.6, 2793187.3 
(ii) In the unmutated group: 1421870.9, 1568594.1, 1803838.1, 2179905.6 
 
In this case, group (i) has 8 elements, and group (ii) has 4 elements. We denote µ1 for 
the mean for group (i) population and µ2 for the mean for group (ii) population. 
 
We assumed that the miRNA expression followed a normal distribution and two groups 
were mutually exclusive. Using these assumptions, our problem satisfied the 
assumptions for the t-test (Appendix A). Note that the miRNA expressions of the two 
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groups may not have an equal variance. We used the Levene test to evaluate the equal 
variance or unequal variance (Appendix A). Note that the t-test uses different equations 
depending on whether there is equal or unequal variance (see Appendix A for details). 
Furthermore, in our case, we chose the significance level α = 0.05. The t-test was a two-
tailed test. 
 
2.5.2 Procedure For Using SAS 
 
We programmed the problem in conformity with the input file format of SAS for the t-
test; see below (for the example of mir-26a-2). 
 
data first; 
input Rep species$ intensity; 
Cards; 
1       M       4271839.8 
1      M       5154553.9 
1     M       2639191 
1       M       3606797 
1     M       3216792.2 
1      M       3688059.3 
1     M       1894745.6 
1   M       2793187.3 
2       UM      1421870.9 
2       UM      1568594.1 
2       UM      1803838.1 
2     UM      2179905.6 
; 
proc ttest; 
 class species; 
 var   intensity; 
  title 'T-test using SAS ttest'; 
run; 
 
We then run the SAS program and obtained the output file below. 
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T-test using SAS ttest     10:56 Friday, August 13, 2004   1 
The TTEST Procedure 
Statistics 
 
 
Variable       patients      N     Mean      Mean     Mean       Std Dev   Std Dev   Std Dev    Std Err 
 
intensity       M               8    2.56E6      3.41E6    4.26E6    671027    1.01E6     2.07E6      358822 
intensity       UM            4   1.22E6     1.74E6     2.27E6    187350    330720    1.23E6      165360 
intensity       Diff (1-2)          479930      1.66E6    2.85E6    606650    868235    1.52E6     531683 
 
 
                                                 T-Tests 
             
Variable      Method          Variances     DF        t Value    Pr > |t| 
             intensity     Pooled               Equal             10          3.13         0.0107 
             intensity     Satterthwaite      Unequal         9.31        4.21         0.0021 
 
 
                                     Equality of Variances 
 
             Variable        Method       Num DF     Den DF       F Value      Pr > F 
             intensity         Folded F          7                  3          9.42            0.0924 
 
 
We first read information of {Pr > F} from the third box above. If {Pr > F} is greater 
than α = 0.05 (this is the case for the example), we conclude that two groups have 
unequal variance (this is the case for the example). Then we read from the second box 
information of {Pr > |t|} according to the equal variance or unequal variance case. If {Pr 
> |t|}< α=0.05, then we conclude that two groups have significant difference in terms of 
their means. In this example, we found {Pr > |t|} = 0.0107 that is less than α = 0.05; So 
the two groups have significant difference in terms of their means of miRNA 
expressions. 
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CHAPTER 3 
Results and Discussion 
 
In total, we characterized thirty B-CLL patient samples in this study. The results include 
(i) the classification of samples into mutated B-CLL and unmutated B-CLL groups, and 
(ii) the characterization of miRNA expressions in these two patient groups. This chapter 
presents these results with discussions. Section 3.1 presents result followed by a 
discussion in section 3.2. 
 
3.1 Results 
 
3.1.1 Patient B-CLL IgVH Mutation Status 
 
We obtained thirty patient peripheral blood samples (B-CLL cells) for the experiments 
conducted in this study. We isolated mononuclear white blood cells using Ficoll Paque. 
These mononuclear white blood cells consist of more than 95% B-cells. We isolated 
 32
total RNA from the B-CLL cells using Trizol. We converted poly A tailed RNA to 
cDNA using reverse transcriptase. We used PCR to amplify the IgVH region from the 
cDNA from each patient using six primer sets. Each primer set contains a unique 
upstream primer corresponding to one of the six human VH leader sequences and a 
constant J-region primer. B-CLL is a monoclonal disease and all B-CLL cells arise from 
a common cell. Therefore, B-CLL cells from each patient have identical rearranged 
variable regions.  
 
Figure 3.1 shows PCR products for patients (PT) 1 to 4 (PCR products for the 
remainder of patients can be found in Appendix B). Table 3.1 summarizes the primers 
sets that gave PCR products for all 30 patients. 
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V3 V5 V1 
1 2 3 4 4
 
Figure 3.1. RT-PCR products for patients (PT) 1-4. PCR produces are separated on a 2 
% agarose gel and stained with ethidium bromide. V1 to V6 correspond to the human 
VH leader sequences primers. M represents a DNA marker. 
 
 
 
 
 
 
 
 
 
 
 
V2 V4 V6 
1 2 3 4M M M2 1 3 
1 2 3 4 2 3 4 2 3 41M M M 1
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Table 3.1. Summary of the IgVH region RT-PCR for thirty patients (PT). (+) indicates 
primer that gave positive RT-PCR products. 
 
 V1 V2 V3 V4 V5 V6  V1 V2 V3 V4 V5 V6 
PT1    +   PT16     +  
PT2     +  PT17   +    
PT3   +    PT18    +   
PT4   +    PT19    +   
PT5   +    PT20   +    
PT6     +  PT21 +      
PT7     +  PT22    +   
PT8   +    PT23   +    
PT9 +      PT24 +      
PT10   +    PT25    +   
PT11    +   PT26   +    
PT12 +      PT27   +    
PT13 +      PT28   +    
PT14     +  PT29   +    
PT15   +    PT30 +      
 
To determine the mutational status of the patients, we sequenced the IgVH region RT-
PCR products using an ABI PRISM 310 Genetic Analyzer (DNA sequencer). A 
summary of the IgVH region sequences for the thirty patients is provided in Appendix 
C. To illustrate the methodology used to calculate the B-CLL patient mutational status, 
we will use PT1 as an example. 
 The sequence of PT1 is: 
 
CCAGATGGGTCTGTCCAGGTGCAGCTCAGCAGTGGGGCNCAGGACTGTTGA
AGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCAG
TGATTACTACTGGACCTGGGTCCGCCAGCCCCCAGGGGGGGGTCTGGAGTG
GATTGGGNAAATCCATCACATTGGAGGTGCCAAATACAATCCGTCCCTCAA
GAGTCCAGTCACCATATCAATGGACACGTCCAAGAGCCAGTTCTCCCTGAG
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ACTGATTTCTGTGACCGCCGCGGACACGGCTGTATATTACTGTGCGAGACTC
CCTCCGGAGTGGTTATTTCCTTTTGACTCCTGGGGCCCGGGGAACCCCGGTC
ACCGTCTCCTCAGGTAC 
 
To determine the germline sequence that PT1 IgVH region is derived from, we matched 
the patient’s sequence to a database of germline sequences using Ig BLAST 
(http://www.ncbi.nlm.nih.gov/igblast). For PT1, the corresponding germline sequence is 
VH4-34 (VH 4 gene family and particularly of VH 4-34 gene of immunoglobulin heavy-
chain variable region). We compared CDR1, CDR2, FWR1, FWR2, and FWR3 
between PT1 and VH4-34 to determine the nucleotide differences in the DNA sequence.  
We then converted the DNA sequence to a protein sequence. We identified S and R 
mutations. S mutations are changes in the DNA sequence that do not change the amino 
acid sequence. R mutations are changes in the DNA sequences that change the amino 
acid sequence. 
 
Calculation of PT1 Mutational Status 
 
CDR1: 
Comparison of CDR1 Region DNA Sequence 
PT1:     GATTACTACTGGACC 
VH4-34:  GGTTACTACTGGAGC 
Nucleotide Mutations: 2 
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Comparison of CDR1 Region Amino Acid Sequence 
PT1:           DYYWT  
VHL4-34:  GYYWS 
Amino Acid mutations: 2 
 
Summary 
R Mutations: 2 
S Mutations: 0 
Sequence length: 15 nucleotides 
 
CDR2: 
Comparison of CDR2 Region DNA Sequence 
PT1:   GAAATCCATCACATTGGAGGTGCCAAATACAATCCGTCCCTCAAGAGT 
VHL4-34:  GAAATCAATCATAGTGGAAGCACCAACTACAACCCGTCCCTCAAGAGT 
Nucleotide Mutations: 8 
 
Comparison of CDR2 Region Amino Acid Sequence 
PT1:            EIHHIGGAKYNPSLKS 
VHL4-34:   EINHSGSTNYNPSLKS 
Amino Acid mutations: 5 
 
Summary 
R Mutations: 5 
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S Mutations: 3 
Sequence length: 48 nucleotides 
 
FWR1: 
Comparison of FWR1 Region DNA Sequence 
PT1: 
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT
CACCTGCGCTGTCTATGGTGGGTCCTTC 
VHL4-34:  
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT
CACCTGCGCTGTCTATGGTGGGTCCTTC 
Nucleotide Mutations: 0 
 
Comparison of FWR1 Region Amino Acid Sequence 
PT1:            QVQLQQWGAGLLKPSETLSLTCAVYGGSF 
VHL4-34:  QVQLQQWGAGLLKPSETLSLTCAVYGGSF 
Amino Acid mutations: 0 
 
Summary 
R Mutations: 0 
S Mutations: 0 
Sequence length: 87 nucleotides 
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FWR2: 
Comparison of FWR2 Region DNA Sequence 
PT1:   TGGGTCCGCCAGCCCCCAGGGGGGGGTCTGGAGTGGATTGGG 
VHL4-34:  TGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGG 
Nucleotide Mutations: 4 
 
Comparison of FWR2 Region Amino Acid Sequence 
PT1:            WVRQPPGGGLEWIG 
VHL4-34:  WIRQPPGKGLEWIG 
Amino Acid mutations: 2 
 
Summary 
R Mutations: 2 
S Mutations: 2 
Sequence length: 42 nucleotides 
 
FWR3: 
Comparison of FWR3 Region DNA Sequence 
PT1: 
CCAGTCACCATATCAATGGACACGTCCAAGAGCCAGTTCTCCCTGAGACTGATTTCTGT
GACCGCCGCGGACACGGCTGTATATTACTGTGCGAGA 
VHL4-34:  
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CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGA 
Nucleotide Mutations: 9 
 
Comparison of FWR3 Region Amino Acid Sequence 
PT1:           PVTISMDTSKSQFSLRLISVTAADTAVYYCAR 
VHL4-34:  RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR 
Amino Acid mutations: 5 
 
Summary 
R Mutations: 5 
S Mutations: 4 
Sequence length: 96 nucleotides 
 
We calculated the mutational status by determining the percentage of nucleotides that 
are mutated in the CDR1, CDR2, FWR1, FWR2, and FWR3. For PT1 the total number 
of mutations is 23 and the total sequence length is 288. The total mismatch frequency is 
23/288 or 7.98 %. In this case, there is 7.98 % (>2 %) difference in the sequence of PT1 
from its germline sequence. Therefore, the B-CLL cells of PT1 went through the 
germinal centre, and its IGVH gene underwent somatic hypermutation. 
 
We also used the R and S mutations to calculate the probability that a B-CLL cell has 
undergone antigen selection using Lossos algorithm (Lossos et al., 2000), which is 
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available at the public website (http://www-stat.stanford.edu/immunoglobin). This 
algorithm calculates a P-value for whether antigen selection has occurred.  
 
Table 3.2 summarizes the results of the analysis. A complete summary of patient 
information is in Appendix D. The sequence data from patient peripheral blood samples 
for PT11 and PT23 are missing CDR and FWR in their sequence.  In Table 3.2 not all 
sample cells obtained P-values which are less than 0.05. Mutation frequency and 
antigen selection probability calculation do not always classify patients into the same B-
CLL subtypes; see Table 3.2. This might be quite natural as both methods have a 
subjective or uncertain component and are used in a different context; in the case of 
method (1) the threshold 2 % is a subjective component, while in the case of method (2) 
two P-values (with the confidence level 0.05) implies another subjective component. 
For our classification, we use only the percentage of mutations to classify B-CLL 
patients as mutated or unmutated.  
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Table 3.2. Upstream primer, P-value, and mutational status of B-CLL patients. ID 
indicates the percentage similarity of patient IgVH gene to its germline sequence. P 
means the probability of antigen selection occurred. M: Mutated, UM: Unmutated. 
 
    CDR FWR  
Sample VH family VH gene % ID P P Pattern 
PT1 VH4 V4-34 92.02% 0.0698 0.0056 M 
PT2 VH5 V5-51 95.83% 0.05143 0.04806 M 
PT3 VH3 V3-74 99.40% 0.1833 0.4291 UM 
PT4 VH3 V3-33 100% 0 1 UM 
PT5 VH3 V3-23 94.60% 0.0902 0.001 M 
PT6 VH5 V5-51 91.90% 0.0257 0.1538 M 
PT7 VH5 V5-51 99% 0.1767 0.4082 UM 
PT8 VH3 V3-74 92.52% 0.1479 0.0279 M 
PT9 VH1 V1-69 99.67% 0.5876 0.2101 UM 
PT10 VH3 V3-11 91.10% 0.1022 0.0581 M 
PT11 VH4 - - - - - 
PT12 VH1 VH1-2 100% 0 1 UM 
PT13 VH1 VH1-69 98.70% 0.0098 0.01536 UM 
PT14 VH5 VH5-51 97.62% 0.1738 0.32905 M 
PT15 VH3 VH3-30 92.80% 0.04432 0.01449 M 
PT16 VH5 VH5-51 95.30% 0.03047 0.04111 M 
PT 17 VH3 VH3-11 99.32% 0.18247 0.09079 UM 
PT 18 VH4 VH4-34 94.40% 0.03408 0.00609 M 
PT 19 VH4 VH4-39 93.70% 0.02146 0 M 
PT 20 VH3 VH3-33 96.94% 0.03843 0.22674 M 
PT 21 VH1 VH1-2 95.92% 0.0013 0.01329 M 
PT 22 VH4 VH4-28 91.31% 0.02418 0.02874 M 
PT 23 VH1 - - - - - 
PT 24 VH1 VH1-3 97.96% 0.19182 0.02691 M 
PT 25 VH4 VH4-34 95.50% 0.55921 0.03206 M 
PT 26 VH3 VH3-9 96.40% 0.02584 0.09563 M 
PT 27 VH3 VH3-48 96.02% 0.07581 0.05312 M 
PT 28 VH3 VH3-11 95.92% 0.001 0.05378 M 
PT 29 VH3 VH3-33 95.24% 0.166 0.13545 M 
PT 30 VH1 VH1-2 100.00% 0 1 UM 
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3.1.2 miRNA Isolation 
 
We isolated miRNA form patient B-CLL cells using the mirVana™ miRNA Isolation 
Kit 1560 (Ambion). We determined the RNA concentrations by measuring the 
Absorbance at 260 nm. We determined the quality of the isolated RNA by separating 
0.25 µg of small RNA on a 15 % polyacrylamide gel and staining the RNA with 
cybergold (Molecular Probes Inc). Figure 3.4 shows an example of RNA isolated from 
B-CLL cells for PT1-9. The remainder of the patients RNA is in Appendix E. We 
normalized the small RNA concentrations from different patient samples using a 
common RNA (usually the 5.8S ribosomal RNA). Table 3.3 summarizes the 
normalized small RNA concentrations for each patient sample. 
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PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8 PT9
 
6
Figure 3.2. Nine miRNA samples (0.25 µg each) and standard mir-16 (0.25 µg) in
15 % polyacrylamide gels, stained by the cybergold. The arrow shows the bands 
were selected to calculate the concentration of the sample. Standard miRNA 16 whic
an indicate size marker that shows the miRNA location in the gel. This standard mir
is shown on furthest right column. 
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Table 3.3. Concentration of miRNA sample of thirty patients. The twelve patient 
samples that are in bold font were selected for miRNA expression analysis.  
 
PT  (ug/ul)   PT (ug/ul) 
1 0.047  16 0.05 
2 0.043  17 0.05 
3 0.069  18 0.034 
4 0.057  19 0.036 
5 0.064  20 0.053 
6 0.239  21 0.032 
7 0.015  22 0.018 
8 0.067  23 0.008 
9 0.026  24 0.015 
10 -  25 0.014 
11 0.027  26 0.018 
12 0.046  27 0.006 
13 0.032  28 0.013 
14 0.047  29 0.016 
15 0.027   30 0.015 
 
0.5 µg of RNA is required for each solution hybridization assay. The total volume of 
RNA for each patient is 100 µl. In our study, we wanted to measure the expression of a 
minimum of eight miRNAs. Therefore, only patients that have a minimum 
concentration of 0.0425 µg/µl are used for miRNA expression analysis. Not all patient 
samples possessed RNA more than this threshold. Only twelve patients satisfied this 
criterion (see Table 3.3). Among these twelve samples, eight are in the mutated B-CLL 
group and four are in the unmutated B-CLL group. 
 
3.1.3 Selection of miRNAs for Analysis 
 
Due to the limited amount of patient RNA, we were limited to analyzing eight miRNAs 
in this study. To choose the miRNAs for our analysis, we focused on miRNAs that are 
located near genomic aberrations that are associated with B-CLL.  
 45
Döhner and Stilgenbauer reported the following B-CLL associated genomic aberrations: 
55 % d13q14, 18 % d11q22-23, 16 % +12, 7 % d17p13, 7 % d6q21, t14q32, +19, where 
d: deletion, +: trisomy, t: translation and the percentage represents the frequency of 
these aberrations in their B-CLL patients (Döhner and Stilgenbauer, 2000; Stilgenbauer 
et al., 2003). Individual genomic aberrations relevant to mutated B-CLL or unmutated 
B-CLL cells have also been reported. For example, +19, d13q14 are relevant to mutated 
B-CLL and d11q22-23, +12, and d6q21 are relevant to unmutated B-CLL (Hamblin et 
al., 1999; Carsten et al., 2003). 
 
We used the UCSC Genome database to search for miRNAs that were located at sites of 
genomic aberrations (http://genome.ucsc.edu/cgi-bin/hgTracks). We found 72 miRNAs 
that were located at specific chromosomal aberrations (Appendix F). To limit this list 
further, we determined miRNA target genes using Target Scan database 
(http://genes.mit.edu/targetscan/index.html). We identified thirty miRNAs that have 
target genes associated with B-CLL or other cancers (Appendix G). Finally, based on 
genomic location and miRNA target, we narrowed the list down to eight miRNAs 
(Appendix H). Specifically, we chose the following miRNAs with their associated 
chromosomal aberration: mir16-1 (deletion 13); let-7i, mir196-2 and mir26a-2 (trisomy 
12); mir-34b and mir-125b (deletion 11); mir-181C and mir-125a (trisomy 19).  
 
3.1.4 Solution Hybridization Assay 
 
We used the solution hybridization assay developed by Ambion (mirVana miRNA 
detection kit) to monitor the expression of specific miRNAs in the patient samples. In 
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total, we tested the expression of eight miRNAs in eight unmutated and four mutated B-
CLL patients.  
 
Three of the eight miRNAs are not expressed in B-CLL patient samples (mir196, mir-
125a, mir-125b, Data not shown). Figures 3.3-3.7 show the solution hybridization assay 
for five miRNAs (mir16-1, let-7i, mir26a-2, mir-34b, and mir-181C).  
 
 
Neg 
UM M 
1:10 1:20 MK Pos 
11 2 3 4 2 3 4 5 6 7 8 
Figure 3.3. Solution Hybridization for mir-16-1. miRNA 16 solution hybridization 
assay products are marked with arrow. The negative controls (Neg) are undigested 
mir16 probes diluted at 10 and 20 times from stock solution. mir-16 probe was used as 
the positive marker (MK). Positive control (Pos) is mir-16 probe with RNase digestion. 
Four unmutated patients (UM) and eight mutated (M) patients are shown. 
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Figure 3.4. Solution Hybridization for Let-7i. Let-7i solution hybridization assay 
products are marked with arrow. The negative controls (Neg) are undigested mir16 
probes diluted at 10 and 20 times from stock solution.mir-16 (MK1) and mir-16+4  
(MK2) probes were used as the positive markers. Positive control (Pos) is mir-16 
probe+4 with RNase digestion. Four unmutated patients (UM) and eight mutated (M) 
patients are shown. 
 
 
 
Neg UM M 
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Figure 3.5. Solution Hybridization for mir-26a-2. miRNA 26a-2 solution hybridization 
assay products are marked with arrow. The negative controls (Neg) are undigested 
mir16 probes diluted at 10 and 20 times from stock solution. mir-16 probe was used as 
the positive marker (MK). Positive control (Pos) is mir-16 probe with RNase digestion. 
Four unmutated patients (UM) and eight mutated (M) patients are shown. 
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Figure 3.6. Solution Hybridization for mir-34b. miRNA 34b solution hybridization 
1:10 1:20 Pos 1 2 3 4 1 2 3 4 5 6 7 8MK 
assay products are marked with arrow. The negative controls (Neg) are undigested mir-
UM M 
Neg 
16+4 probe diluted at 10 and 20 times from stock solution. mir-16+4 probe was used as 
the positive marker (MK). Positive control (Pos) is mir-16+4 probe with RNase 
digestion. Four unmutated patients (UM) and eight mutated (M) patients are shown. 
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Figure 3.7. Solution Hybridization for mir-181c. miRNA 181c solution hybridization 
assay products are marked with arrow. The negative controls (Neg) are undigested mir-
16+4 probe diluted at 10 and 20 times from stock solution. mir-16+4 probe was used as 
the positive marker (MK). Positive control (Pos) is mir-16+4 probe with RNase 
digestion. Four unmutated patients (UM) and eight mutated (M) patients are shown. 
 
3.1.5 SAS Analysis 
 
We analyzed the expression of eight miRNAs in twelve patient samples. We measured 
the intensity of the miRNA bands using a phosphoroimager (Bio Rad Inc). We used t-
statistic analysis to determine a P-value describing the probability that mutated and 
unmutated B-CLL groups differentially expresses a chosen miRNA. We defined 
miRNA as differentially expressed in the two groups if the P-value is less than 0.05. 
The complete SAS analysis is in Appendix I. The results are summarized in Table 3.4. 
The following miRNAs (mir16-1, mir26a-2, let-7i, mir-34b) have a P-value less than 
0.05 and therefore they are differentially expressed in the mutated and unmutated B-
CLL groups. mir-181c has  a P-value of 0.08 and therefore it is not differentially 
expressed in the  mutated and unmutated B-CLL groups. In summary, determined that 
mir26a-2 expression is up-regulated in the mutated B-CLL group and mir16-1, let-7i, 
mir-34b are down-regulated in the mutated B-CLL group. 
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Table 3.4. Eight selected miRNA expressions  
 
miRNA 
 
M-CLL (mean) 
 
UM-CLL (mean) 
 
Location 
 
Type* 
 
P 
 
mir16-1 76468 194760 13q14 Down 0.0489 
mir196-2 n/a n/a 12q13 n/a** n/a 
mir26a-2 3.41E+06 1.74E+06 +12q14.1 Up 0.0107 
let-7i 706010 1.29E+06 12q14.2 Down 0.0296 
mir-34b 76963 166256 11q23 Down 0.0265 
mir-125b n/a n/a 11q24.1 n/a n/a 
miR-181c 338837 268287 19p13.3 ND*** 0.0802 
miR-125a n/a n/a 19q13.4 n/a n/a 
 
*: Take UM-CLL (unmutated B-CLL) as a reference; ** n/a: not available; ***ND: no 
difference. 
 
 
3.2 Discussion 
 
Our study aimed to discover miRNAs that classify the mutated and unmutated sub-
groups of B-CLL. We chose miRNAs since they are involved in developmental process 
(Baehrecke, 2003; Bartel, 2004; Calin et al., 2004) and are associated with specific 
cancers (Chena and Lodish, 2005; Michael et al., 2003). Many miRNAs are also located 
at sites of B-CLL chromosomal abnormalities (Calin et al., 2002). B-CLL chromosomal 
abnormalities with related miRNAs analyzed in this study include: mir16-1 (deletion 
13); let-7i, mir196-2 and mir26a-2 (trisomy 12); mir-34b and mir-125b (deletion 11); 
mir-181C and mir-125a (trisomy 19).  
 
Our experimental results show that the following miRNAs (mir16-1, mir26a-2, let-7i, 
mir-34b) have significant differences in their expressions between the mutated and 
unmutated B-CLL groups. During the completion of this study, Calin et al., (2004) used 
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microarrays to perform genome wide expression profiling of miRNAs. They identified 
the following miRNAs that distinguished mutated and unmutated B-CLL: mir-186, mir-
132, mir-16-1, mir-102, and mir-29c. In Calin et al., (2004) and our study, mir-16-1 is 
the only common miRNA that distinguishes mutated and unmutated B-CLL.  
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CHAPTER 4 
Conclusions and Future Work 
 
This thesis presents a study on miRNA expression in two sub-groups of B-CLL: 
mutated and unmutated B-CLL. The main purpose of the study is to examine whether 
miRNAs can be used as surrogate markers for the unmutated IgVH group of B-CLL 
patients. We analyzed a specific set of miRNAs that were selected based on their 
chromosome location and mRNA targets. In total, we analyzed the following eight 
miRNAs, which are shown together with their associated chromosomal abnormalities: 
deletion 13: mir16-1; trisomy 12: let-7i, mir196-2, mir26a-2; deletion 11: mir-34b, mir-
125b; trisomy 19: mir-181C, mir-125a. We determined the mutational status of thirty 
patient samples and analyzed miRNA expression in twelve of these patients (eight M-
CLL and four M-CLL). The following conclusions can be drawn from our experiment: 
 
(1) miRNAs mir16-1, mir26a-2, let-7i, and mir-34b have significant differences in 
expressions in mutated and unmutated B-CLL subgroups. The confidence level in 
our statistical inference is 95 %. 
(2) miRNA mir-181c has no significant difference in its expression over the two B-
 53
CLL group.  
(3) miRNA mir-16-1 has also been reported to be differentially expressed in mutated 
and unmutated B-CLL (Calin et al., 2004). Therefore, mir-16-1 is a reliable 
surrogate marker for IgVH mutational status. 
 
The present work shows promises for finding differential miRNA expression in 
subtypes of B-CLL. This can not only be used as an alternative way to sub-classify the 
disease, but also have the potential to discover the molecular mechanisms of the disease. 
Some future work may be suggested. (i) Development of a classifier based on miRNAs, 
as a surrogate marker for the unmutated IgVH gene, may be needed in order to increase 
the reliability of this new marker. Nevertheless, it is likely that the miRNA, mir-16-1, 
alone could be an excellent marker. (ii) Global miRNA profiling using microarray will 
be used to screen large sets of human miRNAs in B-CLL. (iii) Correlation of the 
miRNAs expression with their chromosomal abnormalities to determine whether 
specific translocations up or down-regulate miRNA expression. 
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 Appendix A: The significance test and SAS program 
 
A.1 Theory 
 
One of the statistical analyses is to compare two groups, e.g., mutated B-CLL (M-CLL) 
and unmutated B-CLL (UM-CLL). Physical, chemical or biological properties or 
behaviors of the two groups are called responses or variables. Each group has a number 
of elements (or samples in the terminology of applications). Each element gets a 
response. The average of the responses of all elements in a group is one of the statistics 
of the group, which is called mean. The difference between two groups can then be 
represented by the difference between two means. Note that the response or variable is 
random, i.e., what value of the variable for a particular element is uncertain. As such, 
the mean is also a random variable in nature. This implies that the means of two groups 
will always be of different values. In other words, we cannot get any conclusion about 
whether two groups are different or not based on an arithmetic evaluation of the 
difference of their means (they are always different!). Nevertheless, the statistics 
concerns what is so-called “significant” difference. The test for significant difference 
between two groups is generally called the significance test. 
 
Suppose we have two groups (1, 2). We have n1 elements for group 1 and n2 elements 
for group 2. Then we have a mean for group 1 (µ1) and a mean for group 2 (µ2). The 
significance test is based on the following procedure. 
 
There are two types of hypotheses defined as follows. 
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(i) The null (H0): µ1 = µ2 
(ii) The alternative (Ha): µ1 ≠ µ2 
 
H0 states that there is no significant difference between two groups, while Ha states that 
there is significant difference between two groups. 
 
To test the hypotheses above, we define statistics quantities (or statistics if confusion 
does not arise). The most popular statistics in this case is the t-statistics. The t-test is 
named for the testing of the aforementioned hypotheses using the t-statistics. The t-
statistics is defined as follows: 
 
 (i) The variances of the two groups are equal (Pooled model): 
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In the above S is the standard deviation of the sample, X is the response of an element 
in a group, and X  is the mean of the responses of all elements in the group. It is noted 
that in statistics, we have the concept: population and sample. Both are, mathematically, 
a set which contains elements. Yet, the sample is a portion of the population, as we may 
not be able to get all elements of the population. Usually, the mean of a population is 
denoted by µ; while the mean of a sample is denoted by X. 
 
(ii) The variances of the two groups are unequal (Satterthwaite Model): 
 
11 2
2
2
2
2
1
2
1
2
1
2
2
2
2
1
2
1
−




+−







 +
=
n
n
S
n
n
S
n
S
n
S
DF        (I-5) 
 
)(
)µµ()(
2
2
2
1
2
1
2121
n
S
n
S
XXt
+
−−−=        (I-6) 
 
From the above equations, in particular with the t-value and DF value, we can 
determine the P-value from the standard table that can be found from any statistics text 
book (e.g., Berk and Carey, 2004). If a computer aided statistic software program (e.g., 
SAS) is used, the P-value can be calculated by that program automatically. The P-value 
is the probability of the event that the difference between two means is due to some 
chance-based causes rather than some structural-based causes. Therefore, the smaller 
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the P-value the more likelihood the H0 hypothesis is rejected (i.e., in other words two 
groups have significant difference based on their means). There are a couple of things to 
be remarked. 
 
First, in the above procedure, the meaning of “small” needs to be defined. This is done 
by giving the so-called confidence level or significant level; often this value takes 0.10, 
0.05, 0.01 depending on the application domain. The significance level has the same 
value of the type I error in the hypothesis test above, denoted by α. The type I error is an 
error that H0 is correct but is wrongly rejected. 
 
Second, in the above procedure, the procedure to determine the equal variance or 
unequal variance is the Levene test procedure. The Levene test is defined as:  
H0: = =…=  1σ 2σ kσ
Hα: ≠  for at least one pair (i. j).  iσ jσ
where is the standard deviation of sample i (or group i), and k is the total number of 
groups. The test statistics used for the Levene test is the F-statistics which is defined as 
iσ
F-statistics= 
WSV
BSV          (I-7) 
where  BSV: Between-sample-variation, and  
WSV: Within-sample-variation.  
 
The Levene test then proceeds as follows. Given samples or groups (1, 2, …, k) we can 
calculate the F-statistics, say F=1.7059. After that, we have two alternative ways to test 
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the hypothesis. One way is to find the critical F-value (denoted by Fc) given the 
significant level (e.g. α=0.05). The other way is to find the P-value. Note that the 
standard programs are available to perform both calculations. By taking the first way, if 
F > Fc we reject the null hypothesis at α level (e.g. α=0.05) (i.e., the unequal variance 
situation). By taking the second way, if P-value < α, we reject the null hypothesis.  
 
Third, there are two assumptions behind the t-test: (i) the dependent variable (e.g., the 
miRNA expression) should be continuous and follow the normal distribution, and (ii) 
the independent variable (e.g., patient sample) should be mutual exclusive (i.e., each 
element appears either in group 1 or group 2, but not both). For a particular t-test 
program, any departure away from the assumptions may lead to error in the test.  
 
Last, the meaning of difference of two quantities (e.g., µ1 and µ2) could be: (i) µ1≠ µ2, 
(ii) µ1> µ2, and (iii) µ1< µ2. The (i) is called two-tail, while (ii) and (iii) are called one-
tail. As a convention, the standard program will take the two-tail as a default when it 
comes out with the P-value and F-statistics. If a particular problem is on-tail, the 
corresponding P-value and F-statistics must divide by 2.  
 
A.2 Software 
 
SAS is a program which implements many statistical analysis methods, including the 
significance test. In SAS, a particular module or procedure called ‘t-test’ can be used to 
perform the significance test based on the t-statistics (t-test for short). The following 
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example illustrates the input and output data files of SAS for the t-test which includes 
the Levene test. 
 
Table A.1 shows an example of miRNA (mir-26a). The SAS input for this example is 
given in Figure A.1. The SAS output file is given in Figure A.2. From the lower 
portion of Figure A.2 we can find (i) F = 9.42, and (ii) {Pr >F} = 0.0924. Now because 
{Pr >F}> 0.05, the null hypothesis is accepted; in other words, the two groups in the 
example have any equal variance. Then we read out from the output T-Tests, 
specifically the line for the equal variance, the following: {Pr > |t|} = 0.0107. Since {Pr 
> |t|} < 0.05, we conclude that the two groups have significance difference in their 
means. It is noted that the terms (‘std Dev’, ‘std Err’, ‘DF’, ‘Num DF’, ‘Den DF’) are 
not informative to the purpose of the t-test. 
 
Table A.1. The expressions of mir-26a in the two groups (UM, M) 
Rep M UM 
1 4271839.8  
2 5154553.9  
3 2639191  
4 3606797  
5 3216792.2  
6 3688059.3  
7 1894745.6  
8 2793187.3  
9  1421870.9 
10  1568594.1 
11  1803838.1 
12  2179905.6 
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data first; 
input Rep species$ intensity; 
Cards; 
1       M       4271839.8 
1      M       5154553.9 
1     M       2639191 
1       M       3606797 
1     M       3216792.2 
1      M       3688059.3 
1     M       1894745.6 
1   M       2793187.3 
2       UM      1421870.9 
2       UM      1568594.1 
2       UM      1803838.1 
2     UM      2179905.6 
; 
proc ttest; 
 class species; 
 var   intensity; 
  title 'T-test using SAS ttest'; 
run; 
 
Figure A.1. The SAS input file for mir-26a expression 
   
 
 
 
 
 
T-test using SAS ttest     10:56 Friday, August 13, 2004   1 
The TTEST Procedure 
Statistics 
 
 
Variable       patients      N     Mean      Mean     Mean        Std Dev    Std Dev    Std Dev     Std Err 
 
intensity       M               8    2.56E6      3.41E6    4.26E6      671027    1.01E6      2.07E6       358822 
intensity       UM            4   1.22E6     1.74E6     2.27E6     187350    330720     1.23E6       165360 
intensity       Diff (1-2)          479930      1.66E6    2.85E6     606650     868235     1.52E6      531683 
 
 
                                                 T-Tests 
             
Variable      Method          Variances     DF        t Value    Pr > |t| 
             intensity     Pooled               Equal             10          3.13         0.0107 
             intensity     Satterthwaite      Unequal         9.31        4.21         0.0021 
 
 
                                     Equality of Variances 
 
             Variable        Method       Num DF     Den DF      F Value        Pr > F 
             intensity         Folded F              7                 3               9.42             0.0924 
 
Figure A.2. The SAS output file for mir-26a expression 
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Appendix B: RT-PCR results 
 
5 6 7 8 10
6 7 9
5 10 5 6 7 8 9 10
5 6 7 8 9 10 5 6 7 8 9 10
 
Figure B.1. The RT-PCR products from PT5-PT10 analyzed on a 2 % agarose gel, 
stained with the ethidium bromide. 
9
5 8 10
6 7 8 9
12 13 15 16
11
 
V1 V3 V5
V2 V4 V6
11 neg1 neg214 15 16 11 12 13 neg1 neg214 16 11 12 13 neg1 neg214 15
11 12 13 neg1neg214 15 16 12 13 neg1 neg214 15 16 11 12 13 neg1 neg214 15 16
 
Figure B.2. The RT-PCR products of PT11-PT16 analyzed on the 2 % agarose gel, 
stained with the ethidium bromide. 
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V1 V3 V5
V2 V4 V6
17 18 19 20 neg1 neg2 17 18 19 21 neg1 neg2 17 18 19 20 21 neg1 neg2
17 18 19 20 21 neg1 neg2 17 20 21 neg1 neg2 17 18 19 20 21 neg1 neg2
 
Figure B.3. The RT-PCR products of PT17-PT21 analyzed on 2 % agarose gel, stained 
with the ethidium bromide. 
21 20
18 19
24
22 25
 
 
 
V1 V3 V5
V2 V4 V6
22 23 25 26 neg1 neg2 22 23 24 25 26 neg1 neg2 22 23 24 25 26 neg1 neg2
22 23 24 25 26 neg1 neg2 23 24 26 neg1 neg2 22 23 24 25 26 neg1 neg2
 
Figure B.4. The RT-PCR products of PT22-PT26 analyzed on 2 % agarose gel, stained 
with the ethidium bromide. 
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V1 V3 V5
V2 V4 V6
27 28 29 neg1 neg2 30 neg1 neg2 27 28 29 30 neg1 neg2
27 28 29 30 neg1 neg2 27 28 29 30 neg1 neg2 27 28 29 30 neg1 neg2
 
Figure B.5. The RT-PCR products of PT27-PT30 analyzed on 2 % agarose gel, stained 
with the ethidium bromide. 
30 27 28 29
V3 V3
V3 V3
 
 
 
PT17 PT20
V1 V5 V2 V4 V6 V1 V5 V2 V4 V6
PT26 PT23
V1 V5 V2 V4 V6 V4
 
Figure B.6. The reanalysis of RT-PCR products for PT17, PT20, PT 23, and PT26 on a  
2 % agarose gel, stained with the ethidium bromide. 
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Appendix C:  The IGVH gene sequences of 30 Patients 
 
PT1  
CCAGATGGGTCTGTCCAGGTGCAGCTCAGCAGTGGGGCNCAGGACTGTTGA
AGCCTTCGGAGACCCTGTCCCTCACCTGCGCTGTCTATGGTGGGTCCTTCAG
TGATTACTACTGGACCTGGGTCCGCCAGCCCCCAGGGGGGGGTCTGGAGTG
GATTGGGNAAATCCATCACATTGGAGGTGCCAAATACAATCCGTCCCTCAA
GAGTCCAGTCACCATATCAATGGACACGTCCAAGAGCCAGTTCTCCCTGAG
ACTGATTTCTGTGACCGCCGCGGACACGGCTGTATATTACTGTGCGAGACTC
CCTCCGGAGTGGTTATTTCCTTTTGACTCCTGGGGCCCGGGGAACCCCGGTC
ACCGTCTCCTCAGGTAC 
 
PT2 
CCTCCTCCTGGCTGTTCTCCAAGGAGTCTGTGCCGAGGTGGCAGCTGGTGCA
GTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGGTCTCCTGTCA
GGGTTCTGGATTCAGCTTTACCAGCTATTGGATCGGCTGGGTGCGCCAGATG
CCCGGGAAAGGCCTGGAGTGGATGGGAATCATCGATCCTGATGACTCTGAT
ACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAG
TCCATCAGCACCGTCTACCTGCAGTGGGGCAACCTGAGGGCCTCGGACACC
GCCATTTATTACTGTGCGAGACTCGGATATAGTTATGGGCAACTTACGGCGT
ACATCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGTAA 
 
PT3 
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GGTTTTCCTTGTTGCTATTTTAAAAGGTGTCCAGTGTGAGGTGCAGCTGGTG
GAGTCCGGGGGAGGCTTAGTTCAGCCTGGGGGGTCCCTGAGACTCTCCTGT
GCAGCCTCTGGATTCACCTTCAGTAGCTACTGGATGCACTGGGTCCGCCAAC
CTCCAGGGAAGGGGCTGGTGTGGGTCTCACGTATTAATAGTGATGGGAGTA
GCACAAGGTACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
ACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACA
CGGCTGTGTATTACTGTGCAAGAGCCGTAGCGGGTTCGGGGAATTATTATA
ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTA 
 
PT4 
GGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTGCAGCTGGTG
GAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGT
GCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTA
ATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACA
ATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACA
CGGCTGTGTATTACTGTGCGAGAGAATTCCTGAGGTATTACGATTTTTGGAG
TGGCTATAACGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTC
TCCNTCAGGTAA 
 
PT5 
TGGCTTTTTCTTGTGGCTTTTTAAAAGGTGTCCAGTGTGAGGTGCAGTTGTTG
GAATCTGGGGGAGGCTTGGTACAGCCGGGGGGGTCCCTGAGACTCTCCTGT
GCAGCCTCTGGATTCACCTTTAGCAGCCGTGCCATGAGCTGGGTCCGCCAGG
 74
CTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATTAGTGGTAGTGGAGGGA
GGACATATCACGGAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACA
ATTTCAAGAACACAGTGTATCTGCAAATGAACAGCCTGAGGGCCGAGGACT
CGGCCGTATATTACTGTGCGAAAGATATGTATTATAACCCTATGGACTATGA
TACCAGTGCATTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
GGTA 
 
PT6 
AGGTTNCCTGTCTCGTNTGCAGGAGTCTGTGCCGAAGTGCAGCTGGTGCAGT
CCGGANNAGAGGTGAAAAAGCCCGGGGAGTCTCTGACGATCTCCTGTNAGG
GTTNTGGATACAGTCTTTACCAACTACTTGGATCATGCTGGGTGCGCCANAT
GCCCGGGAAAGGCCTGGAGTGGATGGGNAGNATTGATCCTAGTGACTCTTA
TACCAANTACAGCCCGTCCTTCCAAGGCCNCGTCANCATCTCAGTTGACAA
GTCCTATCATCACTGCCTACCTGCAGTGGAGCANCCTGAAGGCCTCGGACA
CTCGCCATGTATTACTGTGCGAGACTTCTCAGGNANGGACNACTGGTTGCCA
NGCT 
 
PT7 
CAAGGAGTCTGTGCCGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAA
AAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTA
CCAANTACTGGATCAGGCTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAG
TGGATGGGGATCATNTATCCTGGTGACTCTGATACCAAATACAGCCCGTCCT
TCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAACACCGCCTACC
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TGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGA
GGACC 
 
PT8 
TNGGGTTTTCCTTGTTGCTATTTTAAAGGTGTCCAGTGTGAGGTGCAGTTGG
TGGAGTCTGGGGGAGGCTCAGTTCAGCCTGGGGGGTCCCTGAGACTCTCCT
GTGGAGCCTCTGGATTCATCTTCAGGAACTACTGGATGCACTGGGTCCGCCA
AGTTCCAGGGAAGGGGCTGGTGTGGGTCTCACGCATTGATAGTGACGGTAT
TGGGACAACTCACGCGGACTCCGTGAAGGGCCGATTCATCACCTCCAGAGA
CAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAGAGTCGAGGA
TATGGCTGTGTATTATTGTGCAAGAGGACACTACTACGATATGGATGTCTGG
GGCCAAGGGACCACGGTCACCGTCTCCTCAGGTA 
 
PT9 
CTCTTCGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTGCAGCTGGTGC
AGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCA
AGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGG
CCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTA
CAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACG
AATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACA
CGGCCGTGTATTACTGTGCGAGACCTGCGGATAGCAGCTCGTCCATATCCTA
CTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTC
AGGTA 
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PT10 
CCTTGTCGCTACTATAAAAGGTGTCCAGTGTCACGTGCAAGTGGTGGAGTTT
GGGGGAGGGTTGGTCAAGTCTGGAGGGTCCCTGACACTCTCCTGTGCAGCC
TCGGGATTCAGCTTCAGTGACTACCAGATGACTTGGGTCCGCCAGCCTCCAG
GGAAGGGGCTGGAGTGGATTTCAGACATTAGCAGTAGTAGTACTTACACNG
AAATACGCAGAATCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCC
AAGAATTTATTGTATCTGCAAATGAACAACGTGAGAGCCGATGACACGGCT
GTGTATTATTGTGCGAGAGGCAAATATTATGGTAGTAGTGGCACTTATTACT
TTGACAACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTA 
 
PT11 
CCTCCTCCTCGGTGGCAGCTCCCAGATGGGTCCTGGTCCAGGTGCAGCTGCA
GGAGTCGGGCGTACGACTGGTGCAATGATGGTTGATATTGCATGTGGACCC
GGCAGTCCCCAGGGGAGGGACTGGAGTGCATTGAATCTATCTAATATTCTG
GGAGCATCAACTACAATCCCTCCCTCAGGAGTCGAGTCACCGTTTCACTAAG
GACGTCCAAGAATTAGTTCTCCCTGAAGTTGAGGTCTGTGACCGCTGCGGAC
ACCGTCGTATATTCGTGTGCGAGAGAGAGGTTGGGGGTTGTCGTAGTGGTG
GTAGCTGCTACGGACGAACTCACAGTACTTCTACTACATGGACGTCTGGGA
CTAAGGGACCTCGGTCACCGTCTCCTCAGGTA 
 
PT12  
TATCTTCTTGGTGGCAGCAGCCACAGGAGCCCACTCCCAGGTGCAGCTGGT
GCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG
CAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAG
 77
GCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGT
GGCACAAACTATGCACAGAAGTTTCAGGGCTGGGTCACCATGACCAGGGAC
ACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGAC
ACGGCCGTGTATTACTGTGCGAGAGGACCTATTTGTAGTGGTGGTAGCTGCT
ACTCGGACCCACCCTGGTACTACTACTACGGTATTGGACGTCTGGGGCCAA
GGGACCACGGTCACCGTCTCCTCAGGTA 
 
PT13 
TTCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGTCCAGCTGGT
GCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTG
CAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACA
GGCCCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCTATCCTTGG
TATAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGA
CAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGA
CACGGCCGTGTATTACTGTGCGAGCTCTTACGATTTTTGGAGTGGTTATCCC
CCTTTCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCNTAGGTA 
 
PT14 
CCTCTCCTGGCTGTTCTCCAGGAGTCTGTGCCGAGGTGAGCTGGTGCAGTCT
GGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGT
TCTGGATACANCTTTACCACCTACTGGATCGGCTGGGTGCGCCAGATGCCCG
GGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATNCCA
GATACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCA
 78
TCANNACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCNGACACCGNCA
TGTATTACTGTGCGAGAC 
 
PT15 
GGTTTCTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCACATGCAGCTGGT
GGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGATCCCTGACACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGGCTATGGCATGCACTGGGTCCGCCAG
GCTCCAGGCAAGGGGTTAGAGTGGGTGGCAGTTATTTCATTTGACGGAAGT
AGTGAATACTATGAAAACTCCGTGAGGGGCCGATTCACCGTCTCCAGAGAC
AATTCCAAGAGCACACTGTATCTGCAAATGGACAGCCTGAGACCTGAGGAC
ACGGCTGTATTTTACTGTGCGAAAGGCCAAAGAGAATTTGGGGGAGCCCCT
GACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTA 
 
PT16 
CGCCTCCTCCTGGCTGTTCTCCAAGGAGTCTGTGCCGANGTGCAGCTGGTGC
AGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTN
AGGNTTCTGGATACANNTTTACCACCTACTGGATCNNCTGGGTGCGCCAGA
TGCCCGGGAAAGGCCTGGAGTGGATGGGGANCATNNATCCTGGTGACTCTG
ATACCANATACAGCCCGTCCTTCCAAGGCCANGTCACCATCTCAGCCGACA
AGTCCATCANCACCGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACA
CCGCCATGTATTACTGTGCGAGNCNNNGTTATNNNGATGNGGNTTATCNAN
ACTACTGCGGCCANGGAACCCAGGTCACCATCTCCTTAAGTACCT 
 
PT17 
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TGGTTTTCCTTGTTGTTATTATAAAAGGTGTCCAGTGTCAGGTGCAGCTGGT
GGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAACTGGATCCGCCAG
GCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGT
ACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGAC
AACGCCAAGAACTCACTGTATCTACAAATGAACAGCCTGAGAGCCGAGGAC
ACGGCCGTGTATTACTGTGCGAGAGCTGTTTCTCGTAGTACCAACTGCTATG
ACGACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGG 
 
PT18 
TCTCCCTGGTGGCAGCTCCCAGATGGGTCGTGTCCCAGGTGCAGCTACAACA
GTGGGGCGCAGGACTATTGAAGTCTTCGGAGACCCTGTCCCTCACCTGCGCT
GTCTATGGTGGGACCTTCAGTGGTTACTACTGGGGCTGGATCCGCCAGCCCC
CAGGGAAAGGGCTGGAGTGGATTGGGGAAATCAATCATGTTGGAAGGAAC
AACCACAGCCCGTCCCTCAAGAGCCGAGTCACCATGTCAGTAGACACGTCC
AAGAACCAATTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCT
CTCTATTACTGTGCGAGGTATAAGGGATATAGTGACTACGATTATTACTTTG
ACTACTGGAGCCAGGGAACCCTGGTCACCGTCTCCNTCAGGTA 
 
PT19 
CTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCCCAGCCTGCAACTGCAG
GAGTCGGGCCCAGGGCTGGTGCAGCCTTCGGAGACCCTGTCCCTCACCTGC
GCTGTCTCTGGTGCCTCCATCAGCACTAATAATTACTACTGGGGCTGGGTCC
GCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGTGTATCCATCATAGTG
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GGAGCACCTACTATAGTCCGTCCCTCAGGAGTCGAGTCATCATGTCCGTAGA
CACGTCCAAGAACCAGTTCTCTCTGAATCTGAACTCTGTGACCGCCGCAGAC
ACGGCTGTGTATTACTGTGCGAAACAGGGTGGCGCCTCTTCCGGGGACTACT
GGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTAC 
 
PT20 
TGGGTTCTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTGCAGCTGG
TGGAGTCTGGGGGAGCCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCT
GTGCAGCGTCTGGATTCACCTTCACTAACTATGGCATGCACTGGGTCCGCCA
GGCTCCAGGCAAGGGGCTGGAGTGGGTGGCACTTATATGGTTTGATGGAAG
TACTAAATACTATGCAGACTCCGTGAAGGGCCGATTTACCATCTCCAGAGA
CAATTCCAAGAACACGCTGTTTCTGCAAATGAAAAGCCTGAGAGCCGAGGA
CACGGCTGTGTATTACTGTGCGAGAGATACCTTAGGTTACCGTGATAGTCGT
GGGTCTAACGGAGGTGTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCC
TCAGGTA 
 
PT21 
CTCTCTTGGTGGCAGCAGCCACAGGAGCCCACTCCCAAGGTGCACGCTGGT
GCAGTCTGGGGCTGAGGTGAAGAAGNCCTGGGGCCTCAGTGAAGGTCTCCT
GCAAGGCTTCTGGATACACCTTCACCGACTACTNTATGCACTGGGTGCGACA
GGCCCCTGGACAAGGGCTTGAGTGGATGGGACGGATCAACCCTGACNGTGG
TGACACAAACTATGCACNGAAGTTTCAGGACAGGGTCACCATGACCAGGGA
CACGTCCATCAGNACAGCCTACATGGANCTGAGCAGGCTGACATCTGACGA
CACGGCCGTGTATTANTGTGCGAGAGCCCACTCTTATTATAGTAGGNAC 
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PT22 
CCTCCTCCTGGTGGCAGCTCCCAGATGGGTCGTGTCTCAGGTGCAGCTGCAG
GAGTCGGGCCCAGGACTGGTGCAGCCTTCGGGGACCCTGTCTCTCACCTGC
GCTGTCTCTGATGGCTCCATCAGCAGTAATAACTGGTGGTGGAGTTGGGTCC
GCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGGACATCTGTCATAGTG
GGTACACCAACTACAACCCGTCCCTCATGAGTCGAGTCACCATGTCAGTAG
ACAAGTCCAAGAATCAGTTCTCCCTGAAGGTGACCTCTGTGAGCGCCGCGG
ACACGGCCGTATATTACTGTGCGAGAGCCCTCGCATACTGTGGTGGGGACT
GCTATCCCACATACTACTACTACCACGGTATGGACGTCTGGGGCCAGGGGA
CCACGGTCACCGTCTNCTTCAGGTA 
 
PT23 
GGGGTTACCTCGTTGCTCTTTTAAGAGGTGTCCAGCGTCACGTGTAGTTGGT
GGAGTCTGGGGGAGGTGTGGTCCAGCCTGGGGGGTCCCTGAGAGTCTCCTG
TGCAGCCTCGGCATTCACCCTCAGAAGCTGTGGGGTCCGCCAGGCTCCAGG
CAAGGGACTGGAGTGGGTGGCATGTCTCATTTAATGGAAGTAACAAATATT
GATGCGAAAGATTCATCTGTCGGTGACAACCCCAAATTAGATTCATCTGTCG
GTGACAACCCCAAATTAGGACGAAGTCCTACTTTGCCATGGACGTCTGGGG
CCAAGGGACCACGGTCACCGTCTCCTTCAGGTAA 
 
PT24 
TATCTTTTTGGTGGCAGCAGCCACAGGTGCCCACTCCCAGGTCCAGCTTGTG
CAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGC
AAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGG
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CCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTA
ACACAAAATATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACA
CATCCGCGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACA
CGGCTGTGTATTACTGTGCGAGAGAACAGTGGCTGGTACGGGTCTACTTTGA
CTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTA 
 
PT25 
CCTCCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGCTACAG
CAGTGGGGCGCAGGACTGTTGAGGCCCTCGGAGACCCTGTCCCTCACCTGC
GCTGTGTATGGTGGGTCCTTCAGTGGTTTCTATTGGAGCTGGATCCGCCAGC
CCCCCGGAAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGC
GCCAACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCATTAGACACG
TCGAAGAGTCAGTTCTCCCTGAGGCTGAGCTCTGTGACCGCCGCGGACACG
GCTGTGTATTACTGTGCGAGAGGCGAGGGTTCGGGGAGTTATTATAGTTACT
TTGACTACTGGGGCCGGGGAACTCTGGTCACCGTCTCCTTAAGGT 
 
PT26 
TGGNTTTCCTTTTGGCTATTTTAAAAGGTGTCCAGTGTGAAGTGCAGCTGGT
GGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTTCATGATTATGGCATGCACTGGGTCCGGCAA
GCCCCAGGGAGGGGCCTGGAGTGGGTCGCAGGTATTACTTGGAATAGTGGT
TACATAGACTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGAC
AACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGCGCTGAGGAC
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ACGGCCTTGTATTACTGTGCAAAAGTTGGAGGCAGTACCTGGTCAAATATTG
ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTA 
 
PT27 
TGGTTTTCCTTGTTGCTATTTTAAAAGGTGTCCAGTGTGAGGTGAGCTGGTG
GATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTG
CAGCCTCTGGATTCACCTTCAGCAGCTATGCCATGAACTGGGTCCGCCAGGC
TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTGGAAC
CATATATTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACtAT
GCCAATAACTCACTGTTTCTGCAAATGAACAGCCTGAGAGACGAGGACACG
GCTGTATATTACTGTGCGAGAGGCCCAGGCTACGATTACGTTTGGGGGAATT
ATCGCCCGACCCTTTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGT
CTCTCAGGTA 
 
PT28 
TGGTTTCCTCTTGTTGTATTTTAAAAGGTGTCCAGTGTGAGGTGCAGCTGGT
GGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTAACTATTGCATGAACTGGGTCCGCCAG
GCTCCAGGGAAGGGGCTGGAGTGGGTCTCACGTATTAGTAGTGATGGTAGT
AATAAATACTATGCATACTCTGTGAAGGGCCGATTCACCATCTCCAGAGAC
AATTCCAAGAACACGCTGTATCTGCAAATGAACAGGCTGAGAGCCGAGGAC
ACGGCTGTGTATTACTGTGCGAAAGAT 
 
PT29  
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GGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTGCAGCTGGT
GGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTG
TGCAGCGTCTGGATTCACCTTCAGTAGTTATGGCATGTACTGGGTCCGCCAG
GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTGTAATGGAAGT
AAAAAATACTATGCAGACTCAGTGAAGGGCCGATTCACCATCTCCAGAGAC
AATCCCAAGAATATGGTATGTCTGCAAATGAACAGTCTGAGAGTCGAGGAC
ACGGGTGTGTATTAATGTGCGAGAGATCCTTTGTGTTCGGTTGGTGGTAATG
GCTACAGGCTACTACCACGGTATGGACGTCTGGGGCCAAGGGACCCGGTCA
CCGTTTCTTCAGGTA 
 
PT30 
TATCTTCTTGGTGGCAGCAGCCACAGGAGCCCACTCCCAGGTGCAGCTGGT
GCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG
CAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAG
GCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGT
GGCACAAACTATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGAC
ACGTCCATCAGCACAGCCTACATGGAGCTGAGCAGGCTGAGATCTGACGAC
ACGGCCGTGTATTACTGTGCGAGAGATCAATGGTTCGGGATTAACTACTTTG
ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGTC 
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Appendix D: Summary of patient information. 
 
Table D.1. Summary of patient information. 
     CDR1+CDR2 FR1+FR2+FR3 
Sample MS VH family VH gene % ID N2 R2/S2 P2 N1 R1/S1 P1 
PT1 M VH4 V4-34 92.02% 10 7/3 0.0698 13 7/6 0.0056 
PT2 M VH5 V5-51 95.83% 3 2/1 0.5143 9 7/2 0.4806 
PT3 UM VH3 V3-74 99.40% 1 1/0 0.1833 1 1/0 0.4291 
PT4 UM VH3 V3-33 100% 0 0/0 0 0 0/0 1.0 
PT5 M VH3 V3-23 94.60% 8 5/3 0.0902 8 3/5 0.001 
PT6 M VH5 V5-51 91.90% 5 5/0 0.0257 7 5/2 0.1538 
PT7 UM VH5 V5-51 99% 1 1/0 0.1767 1 1/0 0.4082 
PT8 M VH3 V3-74 92.52% 9 6/3 0.1479 13 8/5 0.0279 
PT9 UM VH1 V1-69 99.67% 0 0/0 0.5876 1 0/1 0.2101 
PT10 M VH3 V3-11 91.10% 10 8/2 0.1022 18 12/6 0.0581 
PT11  V4 - - - - - - - - 
PT12 UM VH1 VH1-2 100% 0 0/0 0 0 0/0 1.0 
PT13 UM VH1 VH1-69 3 3/0 0.00980 1 0/1 0.01536 
PT14 M VH5 VH5-51 97.62% 2 2/0 0.17380 4 4/0 0.32905 
PT15 M VH3 VH3-30 92.80% 9 7/2 0.04432 12 7/5 0.01449 
PT16 M VH5 VH5-51 95.30% 5 4/1 0.03047 6 4/2 0.04111 
PT17 UM VH3 VH3-11 99.32% 1 1/0 0.18247 1 0/1 0.09079 
PT18 M VH4 VH4-34 94.40% 7 6/1 0.03408 9 4/5 0.00609 
PT19 M VH4 VH4-39 93.70% 10 8/2 0.02146 11 8/3 0.000 
PT20 M VH3 VH3-33 96.94% 4 4/0 0.03843 5 4/1 0.22674 
PT21 M VH1 VH1-2 95.92% 8 7/1 0.00130 4 3/1 0.01329 
PT22 M VH4 VH4-28 91.31% 7 7/0 0.02418 17 10/7 0.02874 
PT23  VH1 - - - - - - - - 
PT24 M VH1 VH1-3 97.96% 2 2/0 0.19182 4 1/3 0.02691 
PT25 M VH4 VH4-34 95.50% 3 2/1 0.55921 10 4/6 0.03206 
PT26 M VH3 VH3-9 96.40% 5 4/1 0.02584 5 4/1 0.09563 
PT27 M VH3 VH3-48 96.02% 5 3/2 0.07581 4 3/1 0.05312 
PT28 M VH3 VH3-11 95.92% 8 7/1 0.001 4 4/0 0.05378 
PT29 M VH3 VH3-33 95.24% 6 4/2 0.166 8 6/2 0.13545 
PT30 UM VH1 VH1-2 100% 0 0/0 0 0 0/0 1.0 
98.70% 
 
CDR = complementarity-determining Region; FR =  framework region; 
R =  number of detected R mutations; S =  number of detected S mutations; 
MS= mutational status. 
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Appendix E: Quality of the isolated small RNA. 
PT11 PT12 PT13 PT14 PT15 PT16 PT17
 
Figure E.1. Quality of the small isolated RNA from PT11-PT17. miRNA concentration 
of 0.25µg miRNA samples of PT11-PT17 and 0.25µg mir-16 probe analyzed on a 15 % 
polyacrylamide gel amd stained with cybergold.  
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PT19 PT20 PT21 PT22 PT23 PT24 PT25 PT26 PT27
Figure E.2. Quality of the small isolated RNA from PT19-PT27. miRNA concentration 
of 0.25µg miRNA samples of PT19-PT27 and 0.25µg mir-16 probe analyzed on a 15 % 
polyacrylamide gel amd stained with cybergold.  
.  
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PT27 PT28 PT29 PT30
 
Figure E.3. Quality of the small isolated RNA from PT27-PT30. miRNA concentration 
of 0.25µg miRNA samples of PT27-PT30 and 0.25µg mir-16 probe analyzed on a 15 % 
polyacrylamide gel amd stained with cybergold.  
.  
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Appendix F: Seventy-two selected miRNAs. 
 
 Table F.1. Seventy-two miRNAs that are located near B-CLL chromosome 
aberrations.  
 
Aberration miRNA Aberration miRNA 
d6p21 hsa-miR-219 +3q13.33 hsa-mir-198 
    
d6q12.2 hsa-miR-206 +3q25.33  hsa-mir-15b 
    
d6q13 hsa-miR-30c +3q25.33  hsa-mir-16-2 
    
d6q13 hsa-miR-30a +3q28 hsa-mir-28 
   hsa-miR-30a*   
  + 8p23.1     hsa-miR-124a-1 
d11q13 hsa-miR-192   
   hsa-miR-194-2 + 8p12.3     hsa-mir-124a-2 
 hsa-miR-139   
  + 8p21.3 hsa-miR-320 
d11q23 hsa-miR-34b   
  + 8q24.2 hsa-miR-30b 
d11q23 hsa-miR-34c   
  + 8q24.22 hsa-miR-30d 
d11q24    hsa-miR-125b   
  +12q13.13    hsa-miR-196-2 
d11q24 hsa-let-7a   
  +12q13.31   hsa-miR-200c 
d11q24 hsa-miR-100 +12q13.31 hsa-miR-141 
    
d13q14   hsa-miR-16-1 +12q14.1    hsa-miR-26a-2 
    
d13q14 hsa-mir-15a +12q14.2 hsa-let-7i 
    
d17p13.3 hsa-miR-22 +12q23.1    hsa-miR-135-2 
    
d17p13.3 hsa-miR-132   
  +19q13.2  hsa-miR-199a 
d17p13.3 hsa-miR-212   
      hsa-miR-199a* 
d17p13.1 hsa-miR-195   
  +19q13.2  hsa-miR-24-2 
d17q11.2 hsa-miR-144   
  +19q13.2  hsa-miR-27a 
d17q11.2 hsa-miR-193   
  +19q13.2 hsa-miR-23a 
d17q21.32 hsa-miR-152   
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  +19q13.3 hsa-miR-7-3 
d17q21.32 hsa-miR-10a   
  +19q13.3 hsa-miR-181c 
d17q21.32     hsa-miR-196-1   
d17q23.2     hsa-miR-142-5p +19q13.33 hsa-miR-150 
     hsa-miR-142-3p   
  +19q13.4 let-7e 
d17q23.2     hsa-miR-301   
  +19q13.4 miR-099b 
d17q23.2   hsa-miR-21   
  +19q13.4 miR-125a 
d18q 11.2     hsa-miR-133a-1   
  +19q13.4 miR-hes1 
d18q 11.2    hsa-miR-1-2  miR-hes2 
   miR-hes3 
+3p22.3     hsa-miR-128b   
    
+3p22.3     hsa-miR-26a-1 t 14q32.31 hsa-miR-127 
   hsa-miR-136 
+3p21.33     hsa-mir-138-1  hsa-miR-299 
   hsa-miR-134 
   hsa-miR-154 
+3p21.31     hsa-mir-191   
  t 14q32.33 hsa-miR-203 
+3p21.2 hsa-let-7g   
  t 18q21 hsa-miR-122a 
+3p21.2     hsa-mir-135-1   
   72 total 
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Appendix G: Thirty selected miRNAs. 
 
Table G.1. Selected 30 miRNAs: their mature sequences and DNA oligonucleotide  
templates 
miRNA miRNA Sequence (Mature) 
 
DNA oligonucleotide  for T7 miRNA Probe (+4Ts and 0T) 
 
hsa-miR-194-2 15uguaacagcaacuccaugugga36 Tgtaacagcaactccatgtgga----cctgtctc 
hsa-miR-34b 14aggcagugucauuagcugauug35 aggcagtgtcattagctgattgttttcctgtctc 
hsa-miR-125b 15ucccugagacccuaacuuguga36 tccctgagaccctaacttgtga----cctgtctc 
hsa-let-7a    5ugagguaguagguuguauaguu26 tgaggtagtaggttgtatagttttttcctgtctc 
hsa-miR-16-1   14uagcagcacguaaauauuggcg35 tagcagcacgtaaatattggcg----cctgtctc 
hsa-mir-15a   14uagcagcacauaaugguuugug35 tagcagcacataatggtttgtgttttcctgtctc 
hsa-miR-22   53aagcugccaguugaagaacugu74 Aagctgccagttgaagaactgt----cctgtctc 
hsa-miR-132 59uaacagucuacagccauggucg80 taacagtctacagccatggtcgttttcctgtctc 
hsa-miR-212 71uaacagucuccagucacggcc91 taacagtctccagtcacggcc----cctgtctc 
hsa-miR-195 15uagcagcacagaaauauuggc35 tagcagcacagaaatattggcttttcctgtctc 
hsa-miR-133a 54uugguccccuucaaccagcugu75 Ttggtccccttcaaccagctgt----cctgtctc 
hsa-miR-124a 52uuaaggcacgcggugaaugcca73 ttaaggcacgcggtgaatgccattttcctgtctc 
hsa-miR-320 48aaaagcuggguugagagggcga70 Aaaagctgggttgagagggcgaa----cctgtctc 
hsa-miR-30b   17uguaaacauccuacacucagc37 tgtaaacatcctacactcagcttttcctgtctc 
hsa-miR-30d 6uguaaacauccccgacuggaag27 Tgtaaacatccccgactggaag----cctgtctc 
hsa-miR-196-2   25uagguaguuucauguuguuggg46 taggtagtttcatgttgttgggttttcctgtctc 
hsa-miR-200c 45aauacugccggguaaugaugga66 Aatactgccgggtaatgatgga----cctgtctc 
hsa-miR-141 60aacacugucugguaaagaugg80 aacactgtctggtaaagatggttttcctgtctc 
hsa-miR-26a-2   14uucaaguaauccaggauaggcu35 Ttcaagtaatccaggataggct----cctgtctc 
hsa-let-7i 6ugagguaguaguuugugcu24 tgaggtagtagtttgtgctttttcctgtctc 
hsa-miR-135-2   23uauggcuuuuuauuccuaugug45 Tatggctttttattcctatgtga----cctgtctc 
hsa-miR-122a   15uggagugugacaaugguguuug37 tggagtgtgacaatggtgtttgtttttcctgtctc 
hsa-miR-199a 6cccaguguucagacuaccuguu27 Cccagtgttcagactacctgtt----cctgtctc 
hsa-miR-24-2   50uggcucaguucagcaggaacag71 tggctcagttcagcaggaacagttttcctgtctc 
hsa-miR-27a 51uucacaguggcuaaguuccgcc72 Ttcacagtggctaagttccgcc----cctgtctc 
hsa-miR-23a 45aucacauugccagggauuucc65 atcacattgccagggatttccttttcctgtctc 
hsa-miR-7-3 31uggaagacuagugauuuuguu51 Tggaagactagtgattttgtt----cctgtctc 
hsa-miR-181c 27aacauucaaccugucggugagu48 aacattcaacctgtcggtgagtttttcctgtctc 
let-7e   8ugagguaggagguuguauagu28 Tgaggtaggaggttgtatagt----cctgtctc 
miR-125a   15ucccugagacccuuuaaccugu37 tccctgagaccctttaacctgtgttttcctgtctc 
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Appendix H: Eight miRNAs chosen for expression analysis. 
 
Table H.1. Eight chosen miRNAs andtheir target mRNAs. 
 
miRNA Targets (human) Function 
Deletion 13:   
  
mir16-1 ENSG00000158796 Death effector Domain-containing protein   
  (FLDED-1), (KE05). 
   
   
Deletion 11:    
mir-34b ENSG00000148400 Neurogenic locus notch homolog protein 
  1recursor (NOTCH 1), (Translocation 
  associated notch protein TAN-1) 
   
mir-125b ENSG00000126929  HIV-1 inducer of short transcripts binding  
  protein; Lymphoma related factor 
   
 ENSG00000128342  Leukemia inhibitory factor recursor (LIF),  
  
(Differentiation stimulating factor), (D 
factor),  
  
(Melanoma derived LPL inhibitor), 
(MLPLI). 
   
 ENSG00000104081 BCL-2 modifying factor. 
   
   
   
Trisomy19:   
mir-181C ENSG00000169635 
Hypermethylated in cancer 2 protein (HIC-
2), 
  
(HIC-3), (HIC1 related gene on 
chromosome 22) 
   
mir-125a ENSG00000116017 Dead ringer like-1 protein  
  
(B-cell regulator of IGH transcription), 
(Bright). 
   
 ENSG00000126929 HIV-1 Inducer of short transcripts binding  
  protein;  lymphoma related factor. 
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 ENSG00000128342 Leukemia inhibitory factor precursor (LIF), 
  
(Differentiation stimulating factor), (D 
factor), 
  (Melanoma derived LPL inhibitor) 
   
   
   
Trisomy12:     
let-7i ENSG00000169635 
Hypermethylated in cancer 2 protein (HIC-
2), 
  
(HIC3),(HIC1-related gene on Chromosome 
22) 
   
mir196-2 ENSG00000148200 Orphan nuclear receptor NR6A1 (Germ cell 
  nuclear factor), (GCNF),(retinoid receptor 
   related testis specific receptor). 
   
mir26a-2 ENSG00000170365  Mothers against decapentaplegic homolog   
  
(SMAD 1), (Mothers against DPP homolog 
1), 
  
(MAD related protein 1), (Transforming 
growth  
  factor beta signaling protein 1),(BSP-1),  
  (HSMAD1),(JV4-1). 
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Appendix I: Output of SAS and the analysis process. 
 
The following is result of the output of SAS and the analysis process: 
mir-34b 
(1) Intensity or expression  
Table I.1. The expressions of mir-34b in the two groups (UM, M) 
Rep M UM 
1 148019  
2 107395.7  
3 23281.6  
4 66177.7  
5 48349.5  
6 168044.3  
7 29177.4  
8 25258.4  
9  242040.9 
10  159247.7 
11  142657.1 
12  121079.5 
 
(2) The SAS input file 
data first; 
input Rep species$ intensity; 
Cards; 
1       M       148019 
1       M       107395.7 
1       M       23281.6 
1       M       66177.7 
1       M       48349.5 
1       M       168044.3 
1       M       29177.4 
1        M       25258.4 
2       UM     242040.9 
2       UM     159247.7 
2      UM     142657.1 
2       UM     121079.5 
; 
proc ttest; 
 class species; 
 var   intensity; 
 
run; 
 title 'T-test using SAS ttest'; 
 
Figure I.1. The SAS input file for mir-34b expression 
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(3) The SAS output file 
                                         T-test using SAS ttest     10:28 Friday, August 13, 2004   1 
                                                        The TTEST Procedure 
                                                                    Statistics 
 
Variable               patients      N        Mean      Mean        Mean     Std Dev   Std Dev   Std Dev     Std Err 
 
intensity              M              8       28995       76963       124931   37936       57377    116777      20286 
intensity             UM              4       82105       166256      250407     29958        52884        197182     26442 
intensity              Diff (1-2)            -166E3      -89293      -12793      39175        56067        98393        34334 
 
                                                                T-Tests 
             Variable       Method           Variances       DF         t Value        Pr > |t| 
             intensity        Pooled              Equal          10           -2.60         0.0265 
             intensity       Satterthwaite    Unequal        6.59        -2.68         0.0334 
 
                                      Equality of Variances 
             Variable       Method          Num DF        Den DF         F Value            Pr > F 
             intensity       Folded F            7                    3                 1.18                 0.9811 
 
Figure I.2. The SAS output file for mir-34b expression 
 
 
let-7i 
(1) Intensity or expression  
Table I.2. The expressions of let-7i in the two groups (UM, M) 
Rep M UM 
1 638895.5  
2 698378  
3 723402.6  
4 687411.5  
5 744980.2  
6 620563.6  
7 759537.4  
8 774914.3  
9  906091 
10  1192292.6 
11  1550496.9 
12  1516398.9 
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(2) The SAS input file 
 
data first; 
input Rep species$ intensity; 
Cards; 
1       M       638895.5 
1       M       698378 
1       M       723402.6 
1       M       687411.5 
1       M       744980.2 
1       M       620563.6 
1       M       759537.4 
1      M       774914.3 
2       UM      906091 
2       UM      1192292.6 
2       UM      1550496.9 
2       UM      1516398.9 
; 
proc ttest; 
 class species; 
 var   intensity; 
  title 'T-test using SAS ttest'; 
run; 
 
Figure I.3. The SAS input file for let-7i expression 
 
(3) The SAS output file 
                                           
                                            T-test using SAS ttest     10:43 Friday, August 13, 2004   1 
The TTEST Procedure 
Statistics 
Variable              patients         N     Mean   Mean        Mean      Std Dev    Std Dev     Std Dev     Std Err 
 
intensity               M                 8    659523    706010      752498     36765       55605        113172     19659 
intensity              UM               4   808642    1.29E6       1.77E6     171838     303338      1.13E6    151669 
intensity              Diff (1-2)        -821E3     -585E3    -35E4       120553     172535      302788   105656 
 
                                                                    T-Tests 
             Variable        Method             Variances    DF      t Value       Pr > |t| 
             intensity         Pooled         Equal       10       -5.54          0.0002 
             intensity        Satterthwaite    Unequal    3.1      -3.83          0.0296 
 
                                     Equality of Variances 
             Variable Method      Num DF      Den DF       F Value          Pr > F 
             intensity    Folded F          3                  7             29.76             0.0005 
 
Figure I.4. The SAS output file for let-7i expression 
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mir-26a-2 
(1) Intensity or expression  
 
Table I.3. The expressions of mir-26a in the two groups (UM, M)          
Rep M UM 
1 4271839.8  
2 5154553.9  
3 2639191  
4 3606797  
5 3216792.2  
6 3688059.3  
7 1894745.6  
8 2793187.3  
9  1421870.9 
10  1568594.1 
11  1803838.1 
12  2179905.6 
 
(2) The SAS input file 
 
data first; 
input Rep species$ intensity; 
Cards; 
1       M       4271839.8 
1       M       5154553.9 
1     M       2639191 
1       M       3606797 
1      M       3216792.2 
1       M       3688059.3 
1       M       1894745.6 
1     M       2793187.3 
2       UM      1421870.9 
2       UM      1568594.1 
2       UM      1803838.1 
2       UM      2179905.6 
; 
proc ttest; 
 class species; 
 var   intensity; 
  title 'T-test using SAS ttest'; 
run; 
 
Figure I.5. The SAS input file for mir-26a expression 
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(3) The SAS output file 
                                  
                                           T-test using SAS ttest     10:56 Friday, August 13, 2004   1 
The TTEST Procedure 
Statistics 
Variable       patients          N       Mean         Mean        Mean        Std Dev      Std Dev       Std Dev      Std Err 
 
intensity     M               8       2.56E6      3.41E6      4.26E6      671027        1.01E6        2.07E6       358822 
intensity          UM              4       1.22E6     1.74E6       2.27E6     187350         330720       1.23E6       165360 
intensity          Diff (1-2)              479930      1.66E6     2.85E6      606650        868235        1.52E6      531683 
 
                                                                  T-Tests 
             Variable     Method       Variances    DF     t Value     Pr > |t| 
             intensity     Pooled             Equal          10        3.13       0.0107 
             intensity    Satterthwaite    Unequal      9.31     4.21         0.0021 
 
                                     Equality of Variances 
             Variable        Method        Num DF      Den DF       F Value       Pr > F 
             intensity        Folded F           7                  3               9.42           0.0924 
 
Figure I.6. The SAS output file for mir-26a expression 
 
 
 
mir-16-1        
(1) Intensity or expression  
Table I.4. The expressions of mir-16-1 in the two groups (UM, M)          
Rep M UM 
1 11304.2  
2 7078.1  
3 109980.3  
4 143141.8  
5 269461.6  
6 37943.9  
7 7116.5  
8 25721  
9  152280.7 
10  256082.4 
11  122779.7 
12  247899 
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(2) The SAS input file 
 
data first; 
input Rep species$ intensity; 
Cards; 
1       M       11304.2 
1      M       7078.1 
1       M       109980.3 
1       M       143141.8 
1       M       269461.6 
1       M       37943.9 
1       M       7116.5 
1       M       25721 
2       UM      152280.7 
2       UM      256082.4 
2       UM      122779.7 
2       UM      247899 
; 
proc ttest; 
 class species; 
 var   intensity; 
 
run; 
 title 'T-test using SAS ttest'; 
 
Figure I.7. The SAS input file for mir-16-1 expression 
 
(3) The SAS output file 
                             
                                   T-test using SAS ttest     10:59 Friday, August 13, 2004   1 
The TTEST Procedure 
Statistics 
Variable                patients        N      Mean        Mean       Mean        Std Dev     Std Dev     Std Dev     Std Err 
 
intensity                   M               8     -1411       76468       154348      61592         93155        189596      32935 
intensity                  UM             4     87742      194760     301779      38099         67255       250765      33628 
intensity                  Diff (1-2)           -236E3    -118E3     -667.9        60234         86206      151286       52790 
 
                                                               T-Tests 
             Variable        Method           Variances     DF          t Value       Pr > |t| 
             intensity         Pooled           Equal           10            -2.24         0.0489 
             intensity    Satterthwaite      Unequal        8.26         -2.51        0.0353 
 
                                     Equality of Variances 
             Variable     Method        Num DF      Den DF         F Value          Pr > F 
             intensity     Folded F          7                   3                 1.92              0.6377 
 
Figure I.8. The SAS output file for mir-16-1 expression 
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mir-181c 
 
(1) Intensity or expression     
Table I.5. The expressions of mir-181c in the two groups (UM, M)          
Rep M UM 
1 328896.6  
2 282554.84  
3 281104  
4 362010.9  
5 371392.2  
6 433773.5  
7 243226.3  
8 407736.9  
9  279577.5 
10  255559.8 
11  226375.7 
12  311634.8 
 
(2) The SAS input file 
 
data first; 
input Rep species$ intensity; 
Cards; 
1       M       328896.6 
1       M       282554.84 
1       M       281104 
1       M       362010.9 
1       M       371392.2 
1       M       433773.5 
1       M       243226.3 
1       M       407736.9 
2       UM      279577.5 
2       UM      255559.8 
2       UM      226375.7 
2       UM      311634.8 
; 
proc ttest; 
 class species; 
 var   intensity; 
  title 'T-test using SAS ttest'; 
run; 
 
Figure I.9. The SAS input file for mir-181c expression 
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(3) The SAS output file 
                                             
                                      T-test using SAS ttest     11:01 Friday, August 13, 2004   1 
The TTEST Procedure 
Statistics 
 
Variable            patients        N       Mean        Mean       Mean     Std Dev     Std Dev     Std Dev    Std Err 
 
intensity             M                8       283114   338837    394560     44069       66653      135656      23565 
intensity            UM              4       210731    268287    325843     20491       36171      134866      18086 
intensity           Diff (1-2)              -10199   70550   151299    41350       59180      103857      36240 
 
                                                                     T-Tests 
             Variable        Method           Variances      DF        t Value      Pr > |t| 
             intensity          Pooled              Equal          10          1.95         0.0802 
             intensity          Satterthwaite     Unequal       9.77       2.37        0.0395 
 
                                     Equality of Variances 
             Variable         Method        Num DF     Den DF      F Value        Pr > F 
              intensity        Folded F         7                      3             3.40        0.3432 
 
Figure I.10. The SAS output file for mir-181c expression 
 
 
 
